Toxicology – Syrup of Ipecac

Core Concept

Syrup of ipecac is an oral emetic that was historically used to induce vomiting after poisoning.

It contains the alkaloids:

• Emetine
• Cephaeline

Although once widely kept in homes and used for gastrointestinal decontamination, ipecac has essentially no role in modern routine poisoning management.

The central modern principle is:

Do not induce vomiting after a poisoning unless specifically directed in an exceptional circumstance by a medical toxicologist or poison center.

⸻

Mechanism of Action

Ipecac produces vomiting through both central and peripheral mechanisms.

Central effect

Cephaeline and related alkaloids stimulate pathways involved in the vomiting response.

Gastrointestinal effect

Emetine and cephaeline irritate the gastrointestinal tract and stimulate visceral afferent pathways.

The result is:

Nausea → retching → repeated vomiting

Vomiting can persist well beyond the initial episode.

⸻

Historical Rationale

Ipecac was originally intended to remove poison from the stomach before substantial absorption occurred.

The theory was:

Ingestion → induce vomiting → expel stomach contents → reduce systemic absorption

However, producing vomiting does not reliably empty the stomach.

Clinical studies failed to demonstrate that routine ipecac administration improves meaningful outcomes after poisoning.

⸻

Why Ipecac Was Abandoned

Routine use declined because:

• It does not reliably remove enough toxin to improve outcomes.
• Vomiting may be delayed.
• Poison absorption continues while waiting for emesis.
• Vomiting can persist.
• Aspiration can occur.
• It may delay activated charcoal or antidotes.
• It can interfere with transport and emergency evaluation.
• Patients may deteriorate neurologically while vomiting.

Therefore:

Routine home, prehospital, emergency-department, and pediatric use is no longer recommended.

⸻

Prehospital Poisoning

The older recommendation to administer ipecac when a patient is far from a healthcare facility is obsolete.

Modern priorities are:

• Contact an appropriate poison-information service or emergency service
• Assess airway, breathing, and circulation
• Identify the substance, amount, and time of exposure
• Follow substance-specific advice
• Arrange appropriate medical assessment when indicated

Distance from a hospital does not by itself justify induced vomiting.

⸻

Pediatric Poisoning

Ipecac was once especially common in pediatric poisonings.

Modern practice specifically moved away from this approach.

Parents and caregivers should not routinely induce vomiting in a child after ingestion.

Children can deteriorate unexpectedly, and vomiting increases the risk of aspiration.

⸻

Caustic Ingestion

Ipecac must not be used after ingestion of corrosive substances such as strong acids or alkalis.

Vomiting would re-expose the:

• Esophagus
• Pharynx
• Mouth
• Airway

to the corrosive material.

This can worsen tissue injury and increase aspiration risk.

⸻

Hydrocarbon Ingestion

Vomiting is particularly undesirable after many hydrocarbon exposures.

Examples include products such as:

• Kerosene
• Gasoline
• Lamp oil
• Some petroleum distillates

The major danger is often pulmonary aspiration, rather than systemic absorption from the gastrointestinal tract.

Inducing vomiting can markedly increase the opportunity for hydrocarbon to enter the lungs.

⸻

Sharp Objects

Vomiting should not be induced after ingestion of:

• Sharp objects
• Jagged foreign bodies
• Other material capable of mechanically injuring the gastrointestinal tract

Forced retrograde movement can cause additional injury.

⸻

Patient With Impaired Consciousness

Ipecac should not be administered when airway protection is impaired.

This includes patients with:

• Significant sedation
• Coma
• Severe confusion
• Loss of protective airway reflexes

Vomiting in these circumstances creates substantial aspiration risk.

⸻

Expected Neurologic Deterioration

Ipecac is also dangerous when the ingested substance may soon produce:

• Seizures
• Rapid sedation
• Coma
• Severe agitation

A patient who is initially awake may lose airway protection while vomiting.

This is one reason poisoning management cannot be based solely on the patient’s initial appearance.

⸻

Persistent Vomiting

The most common adverse effect is prolonged nausea and vomiting.

Consequences can include:

• Dehydration
• Electrolyte abnormalities
• Difficulty administering oral treatments
• Delayed medical care
• Aspiration

Persistent vomiting can also confuse assessment because it may be attributed incorrectly to the original poison.

⸻

Aspiration

Aspiration is one of the most clinically important complications.

Vomited material can enter the respiratory tract and cause:

• Chemical pneumonitis
• Airway obstruction
• Hypoxemia
• Respiratory failure

Risk is particularly high with hydrocarbons and impaired consciousness.

⸻

Mechanical Complications of Forceful Vomiting

Repeated forceful emesis can occasionally cause:

• Mallory-Weiss mucosal tears
• Gastrointestinal bleeding
• Esophageal injury
• Pneumomediastinum
• Rare serious thoracic complications

These risks further weaken any rationale for routine induced vomiting.

⸻

Cardiovascular Effects

Forceful vomiting can produce substantial vagal stimulation.

Possible consequences include:

• Bradycardia
• Presyncope
• Syncope

More importantly, chronic exposure to ipecac can produce direct cardiotoxicity from emetine.

⸻

Chronic Ipecac Abuse

Repeated or prolonged ipecac use can cause serious systemic toxicity.

Emetine accumulates in tissues and can injure:

• Cardiac muscle
• Skeletal muscle

Potential manifestations include:

• Progressive weakness
• Myopathy
• Cardiomyopathy
• Dysrhythmias
• Heart failure
• Electrolyte abnormalities

Severe chronic toxicity can be fatal.

⸻

Eating Disorders and Ipecac

Historically, chronic ipecac misuse occurred in some patients attempting to induce vomiting repeatedly.

This is medically dangerous because emetine toxicity can persist even after use stops.

Unexplained:

• Proximal muscle weakness
• Cardiomyopathy
• Dysrhythmias
• Persistent gastrointestinal symptoms

may warrant consideration of chronic emetine exposure when clinically appropriate.

⸻

Activated Charcoal

Ipecac should not be given simply as preparation for activated charcoal.

Vomiting can:

• Delay charcoal administration
• Cause charcoal to be vomited
• Increase aspiration risk

Activated charcoal itself is now used only for selected adsorbable poisonings when anticipated benefit outweighs risk.

⸻

Antidote Administration

Induced vomiting may interfere with orally administered therapies.

For example, repeated vomiting can prevent reliable delivery or retention of an oral antidote or other necessary medication.

Modern management prioritizes effective, toxin-specific treatment rather than attempting routine emesis first.

⸻

Ipecac vs Gastric Lavage

The older source suggests choosing gastric lavage instead of ipecac in many circumstances.

This also requires modernization:

Neither ipecac nor gastric lavage is routinely recommended for poisoned patients.

Gastric lavage now has, at most, a very narrow role in exceptional potentially life-threatening exposures when performed early by experienced clinicians with appropriate airway protection.

It is not the routine replacement for ipecac.

⸻

Large Tablets and Plant Material

Older practice suggested ipecac for large tablets or plant material that might not pass through a lavage tube.

This is no longer a routine indication.

Management instead depends on:

• Specific toxin
• Toxicity of the exposure
• Time since ingestion
• Formulation
• Gastrointestinal function
• Imaging when relevant
• Availability of more appropriate decontamination or elimination strategies

⸻

Whole-Bowel Irrigation

For selected situations involving material poorly managed by activated charcoal, whole-bowel irrigation may occasionally be considered.

Examples can include selected:

• Sustained-release preparations
• Enteric-coated drugs
• Iron or certain other poorly adsorbed substances
• Drug packets

This is a specialist-directed intervention and does not create a modern role for ipecac.

⸻

Pregnancy

The historical FDA pregnancy letter-category system is obsolete.

More importantly, because ipecac itself has essentially no routine therapeutic role in poisoning, pregnancy rarely creates a situation in which its potential benefits need to be weighed.

Management should instead use appropriate substance-specific supportive and antidotal treatment.

⸻

Ipecac Toxicity

If ipecac itself has been consumed excessively, management is primarily supportive.

Evaluation may include:

• Hydration status
• Electrolytes
• ECG
• Cardiac function when chronic exposure is suspected
• Assessment for aspiration
• Evaluation of muscle weakness

There is no specific antidote for emetine toxicity.

⸻

Modern Gastrointestinal Decontamination Principle

Poison management has shifted away from:

“Remove everything from the stomach.”

Instead, clinicians ask:

• What substance was ingested?
• How toxic is the amount?
• Has it already been absorbed?
• Will decontamination meaningfully change outcome?
• Does the intervention create more risk than benefit?

For most poisonings, supportive care and specific antidotes are more important than gastric emptying.

⸻

Important Modernization of the Older Source

• Syrup of ipecac is an emetic containing emetine and cephaeline.
• It was historically used to induce vomiting after poisoning.
• Routine ipecac administration is obsolete.
• It should not routinely be kept or used as a home poisoning treatment.
• Being far from a healthcare facility is no longer an indication for ipecac.
• Small patient size is not an indication.
• Large tablets or plant material do not create a routine indication.
• Ipecac has not been shown to improve clinically meaningful outcomes in poisoning.
• It can delay activated charcoal, antidotes, transportation, and definitive medical care.
• It is particularly dangerous after caustic or hydrocarbon ingestion.
• It should not be used when consciousness may deteriorate or seizures may occur.
• Persistent vomiting and aspiration are important complications.
• Chronic ipecac exposure can cause emetine-associated myopathy and cardiomyopathy.
• Gastric lavage is not the routine modern alternative to ipecac; lavage itself has only rare, highly selected indications.
• Historical pregnancy categories are obsolete.
• Routine dosing instructions for inducing emesis are no longer clinically appropriate.

⸻

Key Points

• Ipecac induces vomiting through central and gastrointestinal actions of emetine and cephaeline.
• It was once widely used for gastrointestinal decontamination.
• It is no longer recommended routinely for poisoning.
• Clinical benefit has not been demonstrated, while important harms are possible.
• Never routinely induce vomiting after a poisoning.
• Caustic ingestion is especially unsuitable because vomiting can cause repeat corrosive injury.
• Hydrocarbon ingestion is especially unsuitable because vomiting increases aspiration risk.
• Ipecac is unsafe when consciousness may deteriorate or seizures are possible.
• Persistent vomiting can cause dehydration, aspiration, and delays in effective therapy.
• Chronic ipecac misuse can produce serious cardiomyopathy and skeletal myopathy.
• Gastric lavage has not replaced ipecac as routine treatment; it too is reserved for exceptional situations.
• Modern poisoning management emphasizes supportive care, selected activated charcoal, specific antidotes, and toxin-directed treatment rather than induced emesis.

Toxicology – Hyperbaric Oxygen Therapy (HBOT)

Core Concept

Hyperbaric oxygen therapy (HBOT) delivers nearly 100% oxygen while the patient is exposed to pressure greater than normal atmospheric pressure inside a hyperbaric chamber.

In toxicology, its principal established role is in selected patients with carbon monoxide (CO) poisoning.

Older literature proposed HBOT for several other poisonings, but many of these indications have weak or uncertain evidence and are not routine modern practice.

Basic Principle

At normal atmospheric pressure, most oxygen is transported bound to hemoglobin, with only a small amount physically dissolved in plasma.

Increasing ambient pressure while breathing nearly 100% oxygen markedly increases the amount of dissolved plasma oxygen.

This can temporarily improve oxygen delivery even when normal hemoglobin-mediated oxygen transport is impaired.

Hyperbaric vs Normobaric Oxygen

Normobaric oxygen

High-concentration oxygen administered at approximately normal atmospheric pressure.

This is the immediate treatment for suspected significant CO poisoning.

Hyperbaric oxygen

High-concentration oxygen delivered at elevated ambient pressure.

HBOT provides:

• Much higher dissolved plasma oxygen
• More rapid CO elimination
• Very high tissue oxygen tensions

However, the need for HBOT depends on the clinical situation rather than simply the presence of CO exposure.

Hyperbaric Chambers

Two broad designs are used.

Monoplace chamber

• Usually accommodates one patient
• Entire chamber may be pressurized with oxygen
• Direct physical access to the patient during treatment is limited

Multiplace chamber

• Accommodates multiple people
• Chamber is usually pressurized with air
• Patients receive oxygen through masks, hoods, or airway systems
• Trained clinical personnel may remain inside with critically ill patients

The available chamber type can influence whether an unstable patient can safely undergo treatment.

Carbon Monoxide Poisoning

CO causes toxicity through several mechanisms.

It binds hemoglobin with high affinity:

CO + hemoglobin → carboxyhemoglobin (COHb)

This:

• Reduces oxygen-carrying capacity
• Interferes with oxygen unloading to tissues

But CO toxicity is more complex than COHb formation alone.

Cellular Effects of Carbon Monoxide

CO also interacts with intracellular proteins such as:

• Myoglobin
• Mitochondrial cytochromes

Consequences may include:

• Cellular hypoxia
• Oxidative stress
• Mitochondrial dysfunction
• Inflammatory injury
• Lipid peroxidation
• Neurologic and myocardial injury

This helps explain why the COHb concentration does not perfectly predict clinical severity.

How Oxygen Accelerates CO Elimination

CO dissociates from hemoglobin over time.

Increasing inspired oxygen accelerates this process.

Therefore:

Room air → slower CO elimination

100% normobaric oxygen → faster elimination

Hyperbaric oxygen → even faster elimination

HBOT also substantially increases dissolved oxygen available to tissues.

Possible Additional Effects of HBOT

Beyond accelerating CO elimination, HBOT may influence secondary injury pathways associated with CO poisoning.

Proposed effects include reduction of:

• Leukocyte-mediated injury
• Oxidative stress
• Lipid peroxidation
• Post-hypoxic inflammatory processes

These mechanisms have been proposed as explanations for potential neurologic benefit.

Immediate Management of Suspected CO Poisoning

Do not delay oxygen while deciding whether HBOT is appropriate.

Initial management includes:

• Removal from the exposure
• High-concentration oxygen
• Airway and ventilatory support when necessary
• ECG
• Neurologic assessment
• Evaluation for myocardial injury when appropriate
• COHb measurement by co-oximetry
• Assessment for associated smoke-inhalation injuries

HBOT consultation can occur simultaneously.

Pulse Oximetry Limitation

Standard pulse oximetry can appear normal or reassuring in significant CO poisoning.

Conventional pulse oximeters cannot reliably distinguish:

• Oxyhemoglobin
• Carboxyhemoglobin

Therefore:

A normal SpO₂ does not exclude CO poisoning.

Co-oximetry is required to measure COHb accurately.

COHb Concentration

COHb helps confirm exposure but should not be interpreted as a direct toxicity score.

The measured concentration can be affected by:

• Time since exposure
• Duration of oxygen therapy before sampling
• Exposure intensity
• Smoking status
• Ventilation

A patient can therefore have serious neurologic or cardiac toxicity despite a relatively modest COHb concentration measured later.

When HBOT Is Considered for CO Poisoning

There is no universally accepted single threshold that determines treatment.

Urgent hyperbaric consultation is particularly reasonable when significant CO poisoning is accompanied by features such as:

• Loss of consciousness
• Persistent or substantial neurologic abnormalities
• Severe altered mental status
• Seizures
• Significant myocardial ischemia or cardiac injury
• Hemodynamic instability
• Severe metabolic acidosis
• Substantial COHb elevation in the appropriate clinical context
• Pregnancy with clinically significant poisoning

The entire clinical picture matters.

Do Not Use COHb Alone

Older recommendations often relied heavily on fixed COHb thresholds.

Modern assessment places greater emphasis on:

• Neurologic condition
• Cardiac involvement
• Loss of consciousness
• Metabolic abnormalities
• Exposure history
• Pregnancy
• Overall severity

Thus:

Treat the patient, not simply the COHb number.

Neurologic Toxicity

Acute CO poisoning can cause:

• Headache
• Dizziness
• Confusion
• Ataxia
• Syncope
• Seizures
• Coma
• Focal neurologic abnormalities

Neurologic findings are important when considering HBOT.

Delayed Neurologic Sequelae

Some patients develop neurologic or neuropsychiatric problems after apparent initial recovery.

Possible manifestations include:

• Cognitive impairment
• Memory difficulty
• Personality or behavioral changes
• Gait abnormalities
• Movement disorders
• Mood symptoms

These can appear after a symptom-free interval.

Whether HBOT reliably prevents delayed neurologic injury remains an area of uncertainty; clinical trials have produced differing results.

Cardiac Toxicity

The myocardium is highly sensitive to CO-related hypoxia.

Possible manifestations include:

• Chest pain
• Ischemic ECG abnormalities
• Elevated cardiac biomarkers
• Dysrhythmias
• Reduced ventricular function
• Cardiogenic shock

Significant myocardial involvement increases concern for severe poisoning and supports early discussion with a hyperbaric specialist.

Pregnancy

Pregnancy deserves special consideration because:

• CO crosses the placenta.
• Fetal hemoglobin binds CO strongly.
• Fetal CO elimination is slower than maternal elimination.
• Maternal COHb does not reliably reflect fetal exposure.

Therefore, clinicians may use a lower threshold for hyperbaric consultation in significant maternal CO poisoning.

Pregnancy itself is not a contraindication to HBOT when clinically indicated.

Smoke Inhalation

A patient exposed to an enclosed-space fire may have several simultaneous problems:

• Carbon monoxide poisoning
• Cyanide toxicity
• Thermal airway injury
• Pulmonary irritant injury
• Burns
• Trauma

HBOT addresses the CO component but does not replace treatment of these other conditions.

Cyanide Poisoning

Older literature proposed HBOT as an adjunct for severe cyanide poisoning.

It is not a primary modern cyanide antidote.

Management instead centers on:

• Airway and ventilation
• High-concentration oxygen
• Hydroxocobalamin
• Supportive cardiovascular care
• Additional antidotal therapy in selected circumstances

HBOT should not delay established cyanide antidotal treatment.

Hydrogen Sulfide Poisoning

HBOT has also been reported in severe hydrogen sulfide poisoning.

However, evidence is limited.

Modern management primarily involves:

• Safe removal from exposure
• High-concentration oxygen
• Ventilatory support
• Cardiovascular support
• Treatment of seizures and other complications

HBOT may occasionally be discussed for exceptionally severe cases, but it is not established routine therapy.

Methemoglobinemia

Methemoglobinemia impairs hemoglobin’s ability to transport and release oxygen effectively.

Standard treatment of clinically significant acquired methemoglobinemia generally involves:

• Removal of the oxidizing agent
• Oxygen
• Methylene blue when appropriate

HBOT is not routine.

It may be considered as an exceptional rescue strategy when severe tissue hypoxia persists and standard treatment is ineffective or unsuitable.

Carbon Tetrachloride and Chloroform

Older reports proposed HBOT for chlorinated hydrocarbon poisoning to reduce hepatic injury.

This is not an established routine modern indication.

Management of these exposures is predominantly supportive and directed toward organ complications.

Severe Anemia

HBOT can dramatically increase dissolved plasma oxygen.

For this reason, it has occasionally been used as a temporary supportive measure in exceptional cases of profound anemia when adequate oxygen-carrying capacity cannot promptly be restored.

This is a specialized nonroutine indication.

Other Established Non-Toxicologic Uses

HBOT also has applications outside poisoning, including selected cases of:

• Decompression sickness
• Arterial gas embolism
• Gas gangrene
• Certain necrotizing infections
• Radiation tissue injury
• Compromised grafts or flaps
• Selected difficult wounds
• Refractory osteomyelitis

Indications depend on current hyperbaric-medicine criteria.

Absolute Contraindication

The major classic absolute contraindication is:

Untreated pneumothorax

During pressure changes, trapped pleural gas can expand and produce life-threatening tension physiology.

A pneumothorax requiring treatment must therefore be appropriately managed before HBOT.

Recent Chest Surgery

Contrary to the older source, recent thoracic surgery is not automatically an absolute contraindication.

Risk depends on factors such as:

• Residual pneumothorax
• Trapped gas
• Surgical anatomy
• Pulmonary condition

The hyperbaric physician should assess these factors individually.

Ear and Sinus Barotrauma

Pressure changes can cause:

• Ear pain
• Middle-ear barotrauma
• Tympanic membrane injury
• Sinus pain
• Sinus barotrauma

Patients must be able to equalize pressure or receive appropriate preventive management.

Middle-ear barotrauma is among the more common HBOT complications.

Pulmonary Barotrauma

Pressure changes can also affect the lungs.

Patients with certain pulmonary disorders, trapped intrathoracic gas, or significant air-space disease require careful assessment.

Pulmonary barotrauma is uncommon but potentially serious.

Oxygen Toxicity

Very high oxygen partial pressures can cause CNS oxygen toxicity.

The most dramatic manifestation is:

• Generalized seizure

An oxygen-toxicity seizure does not necessarily imply permanent neurologic injury, but it requires immediate management of oxygen exposure and patient safety.

Seizure Risk

A history of epilepsy is generally a relative consideration rather than an absolute contraindication.

Other factors that may lower the seizure threshold include:

• Fever
• Certain medications
• Metabolic abnormalities
• Alcohol withdrawal
• Underlying toxicologic illness

Risks must be balanced against the potential benefit of HBOT.

Claustrophobia

Monoplace chambers can provoke:

• Anxiety
• Panic
• Claustrophobia

Preparation and reassurance may help.

Any sedating medication must be used carefully because it can complicate neurologic and respiratory monitoring.

Temporary Visual Changes

Repeated HBOT exposures can produce temporary refractive changes, particularly myopia.

Longer treatment courses can also contribute to ocular effects such as cataract progression.

These issues are more relevant to repeated treatments than to a single emergency session.

Critically Ill Patients

Transporting an unstable poisoned patient to a hyperbaric facility can itself create risk.

The decision must consider:

• Hemodynamic stability
• Airway requirements
• Ventilator compatibility
• Monitoring capability
• Distance and transport time
• Chamber staffing
• Ability to manage deterioration inside the chamber

HBOT should not compromise essential resuscitation.

Monoplace vs Multiplace in Critical Illness

A multiplace chamber may offer an important advantage because trained personnel can remain physically present with the patient.

Monoplace treatment may limit immediate physical access.

Therefore, chamber capabilities matter when treating:

• Intubated patients
• Hemodynamically unstable patients
• Patients requiring continuous interventions

Timing

When HBOT is chosen for acute CO poisoning, early treatment is generally preferred.

However, the decision should not delay:

• High-concentration normobaric oxygen
• Airway stabilization
• Cardiovascular resuscitation
• Treatment of concurrent poisoning or trauma

Monitoring

Depending on illness severity and chamber capabilities, monitoring may include:

• Continuous ECG
• Blood pressure
• Oxygenation
• Ventilation
• Neurologic status
• Airway and ventilator function
• Signs of barotrauma
• Seizure activity

Equipment used inside hyperbaric chambers must meet appropriate safety requirements.

Important Modernization of the Older Source

• HBOT means high-concentration oxygen delivered at greater-than-atmospheric pressure.
• Its principal toxicologic role is selected carbon monoxide poisoning.
• All suspected significant CO poisoning should receive high-concentration oxygen promptly while HBOT is being considered.
• COHb concentration alone does not accurately determine poisoning severity or the need for HBOT.
• Serious neurologic or cardiac manifestations are particularly important in treatment decisions.
• Pregnancy warrants special consideration because fetal CO kinetics differ from maternal kinetics.
• Evidence that HBOT prevents delayed neurologic sequelae is not completely consistent, so treatment decisions remain individualized.
• HBOT is not a substitute for hydroxocobalamin in cyanide poisoning.
• Evidence supporting HBOT for hydrogen sulfide poisoning is limited.
• HBOT is only an exceptional rescue option for severe refractory methemoglobinemia.
• Routine HBOT for carbon tetrachloride or chloroform poisoning is not supported by modern practice.
• Untreated pneumothorax is the major absolute contraindication.
• Recent thoracic surgery is not automatically an absolute contraindication.
• Middle-ear barotrauma is an important common complication.
• CNS oxygen toxicity can cause seizures.
• Transport and chamber limitations must be weighed against potential benefit in unstable patients.
• Historical rigid pressure/time protocols should not be generalized; treatment profiles are determined by experienced hyperbaric teams.

Key Points

• HBOT increases dissolved plasma oxygen by combining high-concentration oxygen with elevated ambient pressure.
• Its main toxicologic application is selected severe carbon monoxide poisoning.
• It accelerates CO elimination and markedly increases tissue oxygen availability.
• CO toxicity involves more than carboxyhemoglobin alone, including mitochondrial, inflammatory, neurologic, and myocardial injury.
• COHb concentration does not correlate reliably enough with severity to determine treatment by itself.
• A normal standard pulse oximeter reading does not exclude CO poisoning.
• Loss of consciousness, major neurologic abnormalities, myocardial injury, severe acidosis, hemodynamic instability, and pregnancy are important factors when considering hyperbaric consultation.
• High-concentration normobaric oxygen should begin immediately and should not be delayed while arranging HBOT.
• HBOT is not routine definitive therapy for cyanide, hydrogen sulfide, chlorinated hydrocarbon poisoning, or methemoglobinemia.
• Untreated pneumothorax is the major absolute contraindication.
• Important adverse effects include ear/sinus barotrauma, oxygen-toxicity seizures, anxiety/claustrophobia, and less commonly pulmonary barotrauma.
• The decision to use HBOT should incorporate poisoning severity, timing, transport risk, chamber capability, and specialist assessment.

Toxicology – Glucagon

Core Concept

Glucagon is an endogenous peptide hormone best known for increasing blood glucose, but it also has positive chronotropic and inotropic cardiac effects.

In toxicology, its traditional major role is as an adjunct in beta-blocker poisoning.

Its role in calcium channel blocker (CCB) poisoning is much less established, and modern management of severe CCB toxicity relies more heavily on calcium, high-dose insulin euglycemia therapy, vasopressors, and other supportive measures.

Normal Physiologic Role

Glucagon is produced by pancreatic alpha cells, particularly in response to falling blood glucose.

Its metabolic effects include:

• Hepatic glycogenolysis
• Hepatic gluconeogenesis
• Increased blood glucose

Its ability to raise glucose depends partly on available hepatic glycogen stores.

Cardiac Mechanism

Glucagon binds to its own G-protein-coupled receptor rather than the beta-adrenergic receptor.

This activates adenylate cyclase:

Glucagon receptor → adenylate cyclase → ↑ cAMP → ↑ intracellular calcium

Cardiac consequences can include:

• Increased heart rate
• Increased contractility
• Improved cardiac output

Why It Can Work in Beta-Blocker Poisoning

Beta blockers inhibit beta-adrenergic receptor signaling.

Normally:

β-receptor stimulation → ↑ cAMP → increased cardiac activity

Glucagon can increase cAMP through a different receptor pathway.

Therefore:

β receptor blocked + glucagon receptor stimulated → cAMP can still increase

This is why glucagon has historically been described as bypassing beta-receptor blockade.

Beta-Blocker Poisoning

Severe beta-blocker toxicity may cause:

• Bradycardia
• Hypotension
• AV conduction abnormalities
• Cardiogenic shock
• Reduced myocardial contractility

Some agents have additional toxic properties.

For example:

• Propranolol can cause sodium-channel blockade and seizures.
• Sotalol can markedly prolong QT and cause torsades de pointes.

These additional mechanisms require their own targeted management.

Role of Glucagon in Beta-Blocker Toxicity

Glucagon can be considered for clinically important beta-blocker-associated:

• Bradycardia
• Hypotension
• Reduced myocardial contractility

A meaningful improvement in heart rate or blood pressure may support continuation of therapy.

However:

Glucagon should not be regarded as the sole or universally effective antidote for severe beta-blocker poisoning.

Evidence supporting its use is limited compared with the strength of its traditional reputation.

Modern Severe Beta-Blocker Management

Treatment is usually multimodal and may include:

• Airway and ventilatory support
• IV fluids when appropriate
• Atropine as an initial temporizing intervention
• Vasopressors
• Glucagon
• High-dose insulin euglycemia therapy (HIE)
• Correction of electrolyte and acid-base abnormalities
• Sodium bicarbonate for significant sodium-channel blockade
• Magnesium/electrical therapy for appropriate ventricular dysrhythmias
• Extracorporeal life support in selected refractory shock

Treatment should be based on the specific beta blocker and hemodynamic phenotype.

High-Dose Insulin Euglycemia Therapy

HIE has become particularly important for severe cardiogenic shock caused by beta blockers and especially calcium channel blockers.

Insulin can improve myocardial carbohydrate utilization and contractility.

Therapy requires close monitoring of:

• Blood glucose
• Potassium
• Hemodynamics
• Fluid balance

Glucagon and HIE are not mutually exclusive; they may be components of the same resuscitation strategy.

Calcium Channel Blocker Poisoning

Older sources frequently recommended glucagon for severe CCB poisoning.

Modern evidence for meaningful benefit is limited.

Severe CCB toxicity more commonly requires:

• IV calcium
• HIE
• Vasopressors
• Airway/ventilatory support
• Careful fluid management
• Selected rescue therapies for refractory cardiovascular collapse

Thus:

Glucagon is not a primary modern antidote for CCB poisoning.

CCB Toxicity and Hyperglycemia

CCBs, particularly severe poisoning with agents such as verapamil or diltiazem, can impair pancreatic insulin release.

This can produce:

• Hyperglycemia
• Insulin deficiency/resistance
• Reduced myocardial carbohydrate utilization

Marked hyperglycemia can therefore be a useful clue to severe CCB toxicity.

This metabolic disturbance is one reason HIE is important.

Hypoglycemia

Glucagon is also used outside toxicology to treat severe hypoglycemia when rapid oral carbohydrate or IV dextrose is not immediately feasible.

It increases glucose primarily by mobilizing hepatic glycogen.

However, its effectiveness may be reduced when glycogen stores are depleted.

Examples include:

• Prolonged fasting
• Severe malnutrition
• Chronic heavy alcohol use
• Advanced liver disease

When reliable IV access exists, dextrose provides a more direct glucose source.

Insulin and Sulfonylurea Poisoning

Glucagon is not the preferred definitive therapy for severe hypoglycemia from insulin or insulin secretagogues.

Insulin toxicity

Management centers on:

• Dextrose
• Frequent glucose monitoring
• Electrolyte monitoring
• Prolonged glucose support when necessary

Sulfonylurea toxicity

Dextrose corrects hypoglycemia, but glucose administration can stimulate further insulin release.

Octreotide is therefore important for recurrent sulfonylurea-induced hypoglycemia.

Glucagon can also stimulate insulin release, making it poorly suited as definitive treatment for sulfonylurea poisoning.

Nausea and Vomiting

A major practical limitation of glucagon is:

Nausea and vomiting are common, particularly when larger amounts are used.

This is especially concerning in poisoned patients with:

• Depressed consciousness
• Poor airway protection
• High aspiration risk

Airway status must therefore be considered carefully.

Hyperglycemia

Glucagon stimulates hepatic glucose release and can cause transient hyperglycemia.

Blood glucose should be monitored, especially when glucagon is being combined with other metabolic therapies.

Hypokalemia

Glucagon-associated metabolic changes can contribute to reductions in serum potassium.

In severe cardiotoxic poisoning, potassium abnormalities are especially important because they can influence:

• Cardiac conduction
• Dysrhythmia risk
• Response to HIE

Serial electrolyte monitoring is appropriate.

Pheochromocytoma

Glucagon can provoke catecholamine release in patients with pheochromocytoma.

This can produce severe:

• Hypertension
• Tachycardia
• Cardiovascular instability

Known pheochromocytoma is therefore an important precaution/contraindication.

Insulinoma

In a patient with an insulinoma, glucagon-induced hyperglycemia can provoke additional insulin secretion.

This may subsequently cause paradoxical or recurrent hypoglycemia.

Hypersensitivity

Serious allergic reactions are uncommon but possible.

Reported reactions include:

• Rash
• Hypersensitivity
• Rare anaphylaxis

Standard emergency treatment is required if a serious reaction occurs.

Warfarin Interaction

Older reports describe enhanced anticoagulant effects when glucagon is used with warfarin.

This is not usually the central concern during emergency toxicologic resuscitation, but coagulation status may be relevant in patients receiving chronic anticoagulation.

Preparation Issues

Severe beta-blocker poisoning historically required amounts of glucagon far greater than those contained in ordinary outpatient hypoglycemia rescue kits.

This can create practical problems with:

• Hospital supply
• Preparation
• Reconstitution
• Administration volume

Pharmacy involvement should occur early if substantial glucagon therapy is being considered.

Modern commercial formulations and diluents vary, so older warnings about a specific phenol-containing diluent should not be generalized to every current glucagon product.

Resource Limitation

One practical reason glucagon cannot be relied upon as the sole treatment of massive beta-blocker poisoning is that hospitals may not have large quantities immediately available.

Resuscitation should therefore proceed simultaneously with other appropriate therapies rather than waiting for glucagon procurement.

Assessing Response

Glucagon treatment should be assessed clinically by changes in:

• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Cardiac output when available

A biochemical effect or transient increase in heart rate without improved perfusion is not necessarily an adequate therapeutic response.

Refractory Shock

If severe beta-blocker or CCB poisoning remains unstable despite initial treatment, escalation may involve:

• Vasopressor optimization
• HIE
• Mechanism-specific treatment
• Bedside echocardiography/hemodynamic assessment
• Toxicology consultation
• Mechanical circulatory support in selected cases

VA-ECMO may be considered in selected patients with otherwise refractory but potentially reversible cardiogenic shock.

Pregnancy

The historical FDA Category B designation is obsolete.

When glucagon is clinically indicated during pregnancy, treatment should be based on maternal condition and expected benefit.

In severe poisoning, restoring maternal circulation and perfusion is the immediate priority.

Monitoring in Cardiotoxic Poisoning

Monitor:

• Continuous ECG
• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Blood glucose
• Potassium and other electrolytes
• Acid-base status
• Renal function
• Fluid balance

Bedside echocardiography can help distinguish predominant myocardial depression from vasodilatory shock and guide therapy.

Important Modernization of the Older Source

• Glucagon increases intracellular cAMP through its own receptor, bypassing beta-adrenergic receptor blockade.
• Its principal toxicologic role is as an adjunct in beta-blocker poisoning.
• The evidence supporting glucagon in beta-blocker poisoning is more limited than older textbooks sometimes imply.
• It should not delay vasopressors, HIE, or other appropriate therapies in severe shock.
• Glucagon has a much less established role in CCB poisoning and is not a primary modern antidote for it.
• HIE has become central to management of severe CCB cardiotoxicity and is also useful in selected severe beta-blocker poisoning.
• Propranolol-associated sodium-channel blockade requires mechanism-specific treatment rather than glucagon alone.
• Sotalol-associated QT prolongation/torsades requires appropriate dysrhythmia management.
• Glucagon is not preferred definitive therapy for insulin or sulfonylurea poisoning.
• Octreotide is particularly important for recurrent sulfonylurea-associated hypoglycemia.
• Nausea and vomiting are common with glucagon and may create aspiration risk.
• Known pheochromocytoma is an important concern because glucagon can provoke catecholamine release.
• Hospital glucagon supply can become a limiting factor in severe poisoning.
• Formulations and diluents have changed; historical phenol-diluent instructions should not automatically be applied to modern products.
• Historical pregnancy letter categories are obsolete.
• Exact high-dose toxicologic regimens should follow current poison-center or medical-toxicology protocols.

Key Points

• Glucagon activates its own receptor → increases cAMP → increases cardiac contractility and heart rate.
• Because this pathway does not require beta-receptor activation, glucagon can partially bypass beta-blockade.
• Its major toxicologic role is an adjunct for severe beta-blocker poisoning.
• Glucagon is not reliably effective enough to be the only treatment for severe beta-blocker shock.
• HIE and vasopressors are major components of modern treatment for severe cardiotoxic poisoning.
• Glucagon has only a limited role in modern CCB poisoning.
• Propranolol and sotalol have additional toxic mechanisms requiring specific treatment.
• Glucagon also raises blood glucose through hepatic glycogenolysis and gluconeogenesis.
• It may be ineffective for hypoglycemia when hepatic glycogen stores are severely depleted.
• Nausea and vomiting are common and can increase aspiration risk.
• Monitor glucose, potassium, ECG, blood pressure, and tissue perfusion.
• Refractory cardiogenic shock may require advanced mechanical circulatory support in selected patients.

Toxicology – Fomepizole (4-Methylpyrazole)

Core Concept

Fomepizole is the preferred antidote for clinically important methanol and ethylene glycol poisoning.

It works by inhibiting alcohol dehydrogenase (ADH), preventing these parent alcohols from being converted into their more dangerous metabolites.

The key principle is:

Fomepizole prevents further toxic-metabolite formation; it does not directly remove metabolites that have already accumulated.

For severe poisoning, hemodialysis may still be required.

Mechanism of Action

Methanol and ethylene glycol initially have relatively limited intrinsic toxicity compared with their metabolites.

Alcohol dehydrogenase initiates their metabolism.

Fomepizole is a potent competitive inhibitor of ADH:

ADH inhibition → ↓ toxic alcohol metabolism → ↓ formation of toxic metabolites

This allows the unchanged parent alcohol to remain available for elimination or removal by dialysis.

Methanol Metabolism

Methanol undergoes:

Methanol → formaldehyde → formic acid/formate

Formate is responsible for much of the severe toxicity, particularly:

• High-anion-gap metabolic acidosis
• Mitochondrial dysfunction
• Optic nerve injury
• Retinal toxicity
• Visual impairment
• CNS injury

Fomepizole prevents additional formation of formate.

Ethylene Glycol Metabolism

Ethylene glycol undergoes:

Ethylene glycol → glycolaldehyde → glycolate → glyoxylate → oxalate

Important toxic consequences include:

• High-anion-gap metabolic acidosis
• Hypocalcemia
• Calcium oxalate formation
• Acute kidney injury
• Neurologic and cardiovascular toxicity

Glycolate is particularly important in producing the metabolic acidosis.

Why Fomepizole Is Preferred Over Ethanol

Both ethanol and fomepizole inhibit toxic-alcohol metabolism.

However, fomepizole offers several practical advantages:

• More predictable ADH inhibition
• Easier administration
• No therapeutic ethanol intoxication
• Less CNS depression
• Lower risk of hypoglycemia
• No need to maintain a therapeutic blood ethanol concentration
• Fewer fluid-management problems
• Easier use in critically ill patients

Therefore:

Fomepizole has largely replaced ethanol as the preferred ADH inhibitor when available.

When to Consider Fomepizole

Treatment should be considered when methanol or ethylene glycol poisoning is sufficiently suspected from findings such as:

• Credible toxic exposure
• Detectable toxic-alcohol concentration of concern
• High-anion-gap metabolic acidosis compatible with toxic alcohol exposure
• Elevated osmolal gap in the appropriate setting
• Characteristic organ toxicity

Treatment decisions should integrate the whole clinical picture rather than rely on one historical concentration cutoff.

Do Not Delay Treatment in a High-Risk Patient

Confirmatory toxic-alcohol concentrations may take considerable time to return.

When serious methanol or ethylene glycol poisoning is strongly suspected:

Fomepizole should be started promptly rather than waiting for definitive laboratory confirmation.

This is particularly important because toxic metabolites may continue to accumulate while testing is pending.

Osmolal Gap

Early in poisoning, unmetabolized parent alcohol may substantially increase the osmolal gap.

As metabolism proceeds:

Parent alcohol ↓ → osmolal gap may ↓

while:

Acidic metabolites ↑ → anion gap ↑

Therefore:

A normal osmolal gap does not exclude methanol or ethylene glycol poisoning, especially later after exposure.

Anion Gap

The development of high-anion-gap metabolic acidosis often reflects accumulation of toxic metabolites.

Important contributors include:

• Formate in methanol poisoning
• Glycolate in ethylene glycol poisoning

However, the anion gap is neither completely sensitive nor specific and must be interpreted with exposure history and other laboratory findings.

Effect of Fomepizole on Toxic-Alcohol Kinetics

Once ADH is inhibited, metabolism slows dramatically.

This is beneficial because toxic metabolite formation stops, but it also means the parent alcohol can remain in the body much longer.

Without dialysis:

Parent toxic-alcohol half-life becomes prolonged.

This does not mean fomepizole has failed; it reflects successful blockade of metabolism.

Methanol Poisoning

Important manifestations can include:

• Nausea and vomiting
• Headache
• Abdominal discomfort
• CNS depression
• High-anion-gap metabolic acidosis
• Blurred vision
• Photophobia
• Visual-field abnormalities
• Severe visual impairment
• Coma in advanced poisoning

Fomepizole prevents further formate production but cannot instantly reverse established optic injury.

Ethylene Glycol Poisoning

Possible manifestations include:

• CNS depression
• Nausea and vomiting
• Tachycardia
• Metabolic acidosis
• Hypocalcemia
• Muscle spasms or tetany
• Seizures in severe cases
• Acute kidney injury

Urinary calcium oxalate crystals may support the diagnosis but are neither required nor sufficiently specific to establish it.

Fomepizole Does Not Correct Existing Acidosis

If substantial toxic metabolites have already accumulated, simply blocking ADH may not rapidly correct the resulting metabolic acidosis.

Management may also require:

• Supportive resuscitation
• Correction of severe acid-base abnormalities
• Electrolyte management
• Hemodialysis when indicated

Hemodialysis

Hemodialysis efficiently removes methanol and ethylene glycol and can remove important circulating toxic metabolites.

It also rapidly corrects:

• Severe metabolic acidosis
• Major electrolyte abnormalities

Dialysis is considered in selected severe poisoning based on factors such as:

• Significant metabolic acidosis
• Serious clinical deterioration
• Visual toxicity from methanol
• Significant kidney injury in ethylene glycol poisoning
• High toxic-alcohol burden
• Other accepted extracorporeal-treatment indications

Modern decisions should use current toxicology and extracorporeal-treatment guidance rather than a single old concentration threshold.

Fomepizole During Hemodialysis

Fomepizole itself is removed by hemodialysis.

Therefore, its administration schedule must be modified during intermittent hemodialysis to maintain adequate ADH inhibition.

The exact adjustment depends on the dialysis modality and current treatment protocol.

Continuous Kidney Replacement Therapy

Continuous extracorporeal therapies differ from intermittent hemodialysis in their clearance of fomepizole and toxic alcohols.

Dose adjustment therefore should not simply copy an intermittent-hemodialysis regimen.

Current poison-center, nephrology, pharmacy, or toxicology guidance should be followed.

Folate in Methanol Poisoning

Methanol metabolism produces formate.

Folic acid or leucovorin may be used as an adjunct because folate-dependent pathways facilitate conversion of formate toward carbon dioxide and water.

Folate does not replace:

• Fomepizole
• Correction of severe acidosis
• Dialysis when indicated

Adjuncts in Ethylene Glycol Poisoning

Thiamine and pyridoxine have historically been administered to favor metabolism of glyoxylate toward less toxic products.

Their clinical importance is secondary to:

• ADH inhibition
• Supportive care
• Management of acidosis
• Hemodialysis when required

They should never delay definitive therapy.

Concurrent Ethanol

Ethanol also competes for alcohol dehydrogenase.

A patient who has simultaneously consumed ethanol may therefore show delayed development of methanol or ethylene glycol toxicity.

As ethanol disappears:

ADH becomes available → toxic alcohol metabolism increases → toxic metabolites accumulate

Thus an initially well-appearing patient can subsequently deteriorate.

Fomepizole and Ethanol Together

Concurrent ethanol exposure is not, by itself, a reason to withhold fomepizole when fomepizole is clinically indicated.

Fomepizole can inhibit ethanol metabolism and prolong ethanol elimination.

The older concept that a measurable ethanol concentration constitutes an absolute contraindication to fomepizole is therefore too rigid.

Clinical monitoring is required.

Adverse Effects

Fomepizole is generally well tolerated.

Reported effects include:

• Headache
• Nausea
• Dizziness
• Vertigo
• Gastrointestinal symptoms
• Mild transient liver-enzyme abnormalities
• Injection-related reactions

Serious adverse effects are uncommon relative to the consequences of untreated toxic-alcohol poisoning.

Hypersensitivity

Fomepizole should be used cautiously or avoided in patients with a convincing history of serious hypersensitivity to:

• Fomepizole
• Closely related pyrazole compounds

In life-threatening toxic-alcohol poisoning, management requires immediate specialist consideration of alternative ADH blockade and extracorporeal therapy.

Pregnancy

The historical FDA Category C classification is obsolete.

Methanol and ethylene glycol can cause severe maternal and fetal toxicity.

Therefore:

Necessary treatment should not be withheld solely because the patient is pregnant.

Fomepizole may be used when the expected benefit of preventing toxic-metabolite formation outweighs potential treatment risk.

Maternal stabilization is the priority.

Pediatric Poisoning

The same fundamental toxicology applies in children:

Prevent toxic-metabolite formation early.

Children with significant suspected methanol or ethylene glycol poisoning require urgent specialist management.

Treatment is based on weight, clinical severity, laboratory abnormalities, and extracorporeal therapy requirements.

Monitoring

Important monitoring includes:

• Mental status
• Airway and ventilation
• Blood pressure and perfusion
• Blood gas
• Bicarbonate
• Anion gap
• Electrolytes
• Glucose
• Renal function
• Osmolality/osmolal gap when useful
• Methanol or ethylene glycol concentration when available

Additional monitoring depends on the suspected alcohol.

Methanol-Specific Monitoring

Pay particular attention to:

• Visual symptoms
• Visual acuity when feasible
• Neurologic deterioration
• Severity of metabolic acidosis

Severe visual toxicity is an important marker of clinically significant formate exposure.

Ethylene Glycol-Specific Monitoring

Pay particular attention to:

• Creatinine
• Urine output
• Calcium
• Neuromuscular manifestations of hypocalcemia
• Evidence of acute kidney injury

Urinary crystals may be sought but should not determine treatment by themselves.

Stopping Fomepizole

Therapy should not be stopped merely because the patient appears clinically improved.

Discontinuation depends on factors such as:

• Toxic-alcohol concentration
• Resolution of clinically important acidosis
• Clinical stability
• Completion of dialysis when applicable
• Confidence that ongoing toxic-metabolite production is no longer clinically important

Current institutional or poison-center protocols should guide the endpoint.

Important Modernization of the Older Source

• Fomepizole is generally the preferred antidote for methanol and ethylene glycol poisoning.
• It inhibits alcohol dehydrogenase and prevents formation of additional toxic metabolites.
• It does not directly neutralize formate, glycolate, or oxalate already produced.
• Severe poisoning may therefore still require hemodialysis despite timely fomepizole.
• Treatment should not be delayed for confirmatory toxic-alcohol levels when clinical suspicion is high.
• A normal osmolal gap does not exclude late poisoning.
• The osmolal gap tends to be more prominent while parent alcohol remains, whereas the anion gap rises as acidic metabolites accumulate.
• Historical fixed concentration thresholds should not be used as the sole basis for starting antidote or dialysis.
• Fomepizole substantially prolongs the elimination of unmetabolized methanol and ethylene glycol when dialysis is not performed.
• Hemodialysis removes fomepizole, so the administration schedule must be adjusted during extracorporeal therapy.
• Concurrent ethanol is not an absolute contraindication to fomepizole.
• Fomepizole can slow ethanol elimination.
• Folate is an adjunct for methanol poisoning.
• Thiamine and pyridoxine are secondary adjuncts in ethylene glycol poisoning and should not distract from definitive treatment.
• Historical FDA pregnancy categories are obsolete.
• Exact dosing and dialysis adjustments should follow current toxicology, pharmacy, and extracorporeal-treatment protocols rather than older fixed regimens.

Key Points

• Fomepizole inhibits alcohol dehydrogenase.
• It is the preferred antidote for significant methanol and ethylene glycol poisoning.
• Methanol toxicity is largely caused by formate, particularly producing acidosis and optic toxicity.
• Ethylene glycol toxicity is largely caused by metabolites including glycolate and oxalate, producing acidosis and renal injury.
• Fomepizole prevents additional toxic-metabolite formation but does not remove metabolites already present.
• A normal osmolal gap does not exclude toxic-alcohol poisoning.
• Do not delay treatment in a strongly suspected severe exposure while waiting for definitive levels.
• Hemodialysis may still be necessary for severe poisoning.
• Fomepizole is dialyzable, requiring protocol-specific adjustment during hemodialysis.
• Folate is an adjunct in methanol poisoning.
• Concurrent ethanol can delay toxic-alcohol manifestations and can itself persist longer after fomepizole.
• Fomepizole is generally safer and easier to manage than therapeutic ethanol.

Toxicology – Flumazenil

Core Concept

Flumazenil is a competitive antagonist at the benzodiazepine binding site of the GABA-A receptor.

It can rapidly reverse benzodiazepine-induced sedation, but its role in toxicology is highly selective because reversal can precipitate:

• Seizures
• Acute benzodiazepine withdrawal
• Agitation
• Dysrhythmias in dangerous mixed overdoses

For most patients with an unknown or intentional overdose, supportive airway and respiratory care is safer than routine flumazenil.

Mechanism of Action

Benzodiazepines bind to an allosteric site on the GABA-A receptor and enhance inhibitory GABAergic neurotransmission.

Flumazenil competitively occupies this benzodiazepine site and reverses many benzodiazepine effects.

It can improve:

• Sedation
• Psychomotor impairment
• Some benzodiazepine-associated respiratory depression

It does not directly antagonize:

• Opioids
• Ethanol
• Barbiturates
• Antipsychotics
• Most other sedative-hypnotics

Important Pharmacology

Flumazenil generally acts rapidly but has a relatively short duration.

Many benzodiazepines last substantially longer.

Therefore:

Flumazenil wears off → benzodiazepine effect persists → sedation can recur

This is called resedation.

A transient response does not mean the patient is safe for immediate discharge.

Primary Modern Role

The clearest indication is reversal of iatrogenic benzodiazepine sedation in a carefully selected patient.

A typical favorable situation is:

• Benzodiazepine was administered medically
• Dose and exposure are known
• No dangerous co-ingestants are suspected
• Patient is not benzodiazepine dependent
• No important seizure risk is present

This is substantially different from an undifferentiated overdose patient.

Accidental Pediatric Exposure

Flumazenil may also be considered in selected young children with an isolated accidental benzodiazepine exposure when:

• The exposure is reliably known
• No proconvulsant co-ingestion is suspected
• Benzodiazepine dependence is not relevant
• Reversal offers a meaningful clinical benefit

Even then, supportive care is often sufficient.

Benzodiazepine Overdose

Isolated benzodiazepine poisoning typically produces:

• Drowsiness
• Slurred speech
• Ataxia
• Confusion
• Reduced consciousness

Severe respiratory depression is less typical with an isolated benzodiazepine exposure than with combinations involving:

• Opioids
• Ethanol
• Other sedatives

Management is primarily supportive.

Why Flumazenil Is Not Routinely Used

Benzodiazepines themselves have anticonvulsant activity.

In a mixed overdose, that anticonvulsant effect may actually be suppressing seizures caused by another drug.

Giving flumazenil can abruptly remove this protection:

Benzodiazepine effect blocked → proconvulsant co-ingestant remains → seizure emerges

This is the major toxicologic danger.

Mixed Overdose

Flumazenil should generally be avoided when the ingestion is unknown or a dangerous co-ingestant is possible.

Particularly concerning substances include:

• Tricyclic antidepressants
• Bupropion
• Cocaine and other stimulants
• Isoniazid
• Theophylline
• Other seizure-producing drugs

A patient with an intentional multidrug overdose is therefore usually a poor candidate.

Tricyclic Antidepressant Poisoning

TCA poisoning is a particularly important contraindication.

Features suggesting significant TCA or other sodium-channel-blocking toxicity include:

• QRS widening
• Terminal R wave in aVR
• Hypotension
• Ventricular dysrhythmias
• Seizures
• Anticholinergic findings

Flumazenil may remove benzodiazepine-mediated seizure suppression while leaving the dangerous sodium-channel blockade unchanged.

Sodium bicarbonate, not flumazenil, is the key treatment for significant TCA sodium-channel toxicity.

Chronic Benzodiazepine Use

A patient who regularly uses benzodiazepines may develop physiologic dependence.

Abrupt receptor antagonism can precipitate withdrawal.

Possible manifestations include:

• Anxiety
• Agitation
• Tremor
• Autonomic activation
• Severe withdrawal
• Seizures

Therefore, chronic benzodiazepine use or likely dependence is an important reason to avoid routine flumazenil.

Benzodiazepines Used for Seizure Control

Flumazenil is especially hazardous when benzodiazepines are being used therapeutically to suppress seizures.

Removing their anticonvulsant effect can provoke recurrent or refractory seizures.

This includes patients with:

• Epilepsy treated with benzodiazepines
• Status epilepticus receiving benzodiazepine therapy
• Toxicologic seizures being controlled with benzodiazepines

Unknown Coma

Historically, flumazenil was proposed as a diagnostic test for benzodiazepine poisoning.

That role has largely fallen out of favor.

A response may indicate a benzodiazepine effect, but it does not prove that benzodiazepines are the only cause of coma.

More importantly, a diagnostic trial can create unnecessary seizure risk.

Therefore:

Flumazenil should not be used routinely as a diagnostic component of the old “coma cocktail.”

No Response to Flumazenil

Failure to awaken does not by itself establish a particular diagnosis.

Other possibilities include:

• Opioid poisoning
• Ethanol
• Other sedatives
• Hypoglycemia
• Stroke
• Head injury
• Postictal state
• Metabolic encephalopathy
• CNS infection
• Mixed poisoning

Management should return to systematic evaluation of altered mental status.

Respiratory Depression

When benzodiazepine poisoning causes depressed consciousness:

Airway positioning, oxygenation, ventilation, and supportive care remain the foundation of treatment.

Flumazenil should not substitute for appropriate airway management.

If opioids may be contributing, naloxone addresses the opioid component; flumazenil does not.

Seizures After Flumazenil

Seizures are the most clinically important complication.

Risk is increased by:

• Benzodiazepine dependence
• Preexisting seizure disorder
• Proconvulsant co-ingestion
• TCA poisoning
• Benzodiazepines being used to control seizures

Management can be challenging because the benzodiazepine receptor has been antagonized.

Severe seizures require immediate toxicology-directed seizure management and supportive care.

Why Benzodiazepines May Initially Work Poorly

Because flumazenil competes at the benzodiazepine receptor site, conventional benzodiazepine anticonvulsant effects may temporarily be harder to achieve following significant antagonism.

This is another reason to avoid unnecessary flumazenil in patients at meaningful seizure risk.

Resedation

Flumazenil is frequently shorter acting than the benzodiazepine involved.

After initial awakening, patients can again develop:

• Somnolence
• Reduced consciousness
• Respiratory depression

Therefore, continued observation is required.

Repeated antidote administration should not be used merely to avoid appropriate airway support in a high-risk poisoning.

Adverse Effects

Possible adverse effects include:

• Anxiety
• Agitation
• Nausea
• Vomiting
• Dizziness
• Headache
• Tremor
• Sweating
• Emotional distress

More serious complications include:

• Seizures
• Acute withdrawal
• Dysrhythmias
• Recurrent sedation after the antagonist wears off

Vomiting in a still-sedated patient also creates aspiration risk.

Liver Disease

Flumazenil is primarily cleared hepatically.

Significant hepatic impairment can reduce clearance and prolong its effects.

Renal dysfunction has substantially less influence on elimination.

ECG Before Flumazenil

In a suspected overdose, ECG findings can help identify patients in whom flumazenil would be hazardous.

Particular concern includes:

• QRS widening
• Significant QT abnormalities
• Ventricular dysrhythmia
• Other evidence suggesting cardiotoxic co-ingestion

An abnormal ECG in an unknown overdose should increase caution rather than encourage diagnostic flumazenil use.

Agitated or Sympathomimetic Patient

A patient with:

• Marked agitation
• Tachycardia
• Hypertension
• Hyperthermia
• Diaphoresis
• Seizures

does not fit a straightforward isolated benzodiazepine toxidrome.

In such circumstances, flumazenil is unlikely to provide meaningful benefit and may increase seizure risk.

Pregnancy

The historical FDA Category C designation is obsolete.

Use during pregnancy should depend on:

• Clinical necessity
• Severity of sedation
• Maternal airway and respiratory status
• Likelihood of benzodiazepine dependence
• Possibility of mixed poisoning

Supportive stabilization of the pregnant patient remains the priority.

Monitoring After Flumazenil

Monitor for:

• Level of consciousness
• Airway protection
• Respiratory rate and effort
• Oxygenation and ventilation
• Heart rate and blood pressure
• ECG when overdose is suspected
• Seizures
• Withdrawal
• Recurrent sedation

Observation duration depends on the benzodiazepine involved, co-ingestants, clinical course, and reason flumazenil was administered.

A Useful Candidate Profile

Flumazenil is most reasonable when all or nearly all of the following are present:

• Clear isolated benzodiazepine effect
• Known exposure
• No chronic benzodiazepine dependence
• No seizure disorder requiring benzodiazepines
• No proconvulsant co-ingestion
• No concerning ECG evidence of mixed cardiotoxic poisoning
• Reversal provides a meaningful clinical benefit

The further the patient deviates from this profile, the less attractive flumazenil becomes.

Important Modernization of the Older Source

• Flumazenil is a competitive antagonist at the benzodiazepine site of the GABA-A receptor.
• Its modern role in overdose is much narrower than older references suggest.
• It should not routinely be used to diagnose benzodiazepine overdose or unexplained coma.
• Supportive airway and respiratory management is usually sufficient for isolated benzodiazepine poisoning.
• The best-established use is reversal of known iatrogenic benzodiazepine sedation in a carefully selected, nondependent patient.
• Selected isolated accidental pediatric exposures may also be considered.
• Unknown or intentional mixed overdose is generally a poor setting for flumazenil.
• TCA or other proconvulsant co-ingestion substantially increases concern for seizures.
• QRS widening or other evidence of sodium-channel blockade is a strong warning against its use.
• Chronic benzodiazepine exposure can result in abrupt withdrawal and seizures after reversal.
• Flumazenil may wear off before the benzodiazepine, producing resedation.
• Awakening after flumazenil does not prove benzodiazepines were the sole cause of altered consciousness.
• Historical pregnancy letter categories are obsolete.
• Exact dosing should follow current product and clinical protocols rather than being used as a routine empiric “coma reversal” strategy.

Key Points

• Flumazenil reverses benzodiazepine effects by competitively blocking their GABA-A receptor binding site.
• It is not routinely recommended for benzodiazepine overdose.
• Most isolated benzodiazepine poisonings are managed with supportive care.
• Its clearest role is carefully selected reversal of iatrogenic benzodiazepine sedation.
• The major danger is precipitating seizures or acute benzodiazepine withdrawal.
• Avoid routine use when benzodiazepine dependence, epilepsy, unknown co-ingestion, TCA toxicity, or another proconvulsant exposure is possible.
• A widened QRS in an overdose is an important warning against flumazenil.
• Flumazenil does not reverse opioids, ethanol, barbiturates, or other non-benzodiazepine causes of coma.
• Its duration may be shorter than the ingested benzodiazepine, so resedation can occur.
• A temporary awakening does not establish that benzodiazepines were the only toxicant.
• Airway and ventilation remain the priorities in a sedated poisoned patient.

Toxicology – Calcium Disodium EDTA (CaNa₂EDTA)

Core Concept

Calcium disodium ethylenediaminetetraacetate (CaNa₂EDTA) is a parenteral metal chelator used primarily for significant lead poisoning.

The most important safety distinction is:

CaNa₂EDTA ≠ disodium EDTA (Na₂EDTA).

They are not interchangeable. Disodium EDTA can chelate circulating calcium and cause profound, potentially fatal hypocalcemia.

For lead poisoning, the formulation of interest is calcium disodium EDTA.

Mechanism of Action

CaNa₂EDTA contains calcium already incorporated into the chelator complex.

Lead has a greater affinity for EDTA than calcium does, so lead can displace calcium:

CaNa₂EDTA + Pb → Pb–EDTA complex

The resulting lead chelate is water soluble and eliminated predominantly through the kidneys.

This increases urinary lead excretion and lowers the readily exchangeable lead burden.

What Chelation Does

Chelation can reduce circulating and accessible tissue lead.

However, it does not instantly remove the entire body burden because substantial lead may be stored in:

• Bone
• Teeth
• Soft tissues

Lead can later redistribute from these compartments back into blood.

Therefore, rebound in blood lead concentration after chelation is expected to some degree and does not automatically indicate treatment failure.

Lead Toxicity

Lead interferes with numerous cellular processes, including:

• Heme synthesis
• Enzyme function
• Calcium-dependent signaling
• Mitochondrial function
• Neurologic development

Children are particularly vulnerable to the neurodevelopmental effects of chronic exposure.

Clinical Features of Lead Poisoning

Possible manifestations include:

Neurologic

• Irritability
• Behavioral or cognitive changes
• Headache
• Peripheral neuropathy
• Encephalopathy
• Seizures
• Coma in severe poisoning

Gastrointestinal

• Abdominal pain
• Constipation
• Nausea
• Vomiting
• Anorexia

Hematologic

• Anemia
• Impaired heme synthesis

Renal

• Tubular dysfunction
• Chronic nephropathy with substantial exposure

Lead Encephalopathy

Lead encephalopathy is a medical emergency.

Possible findings include:

• Persistent vomiting
• Altered mental status
• Ataxia
• Seizures
• Cerebral edema
• Coma

Treatment requires urgent specialist-directed chelation and intensive supportive care.

Role of CaNa₂EDTA

CaNa₂EDTA is most important when significant lead poisoning requires parenteral chelation, particularly when:

• Severe toxicity is present
• Oral treatment cannot be used reliably
• Lead encephalopathy is present as part of a specialist-directed regimen

For many patients with less severe poisoning who can tolerate oral therapy, succimer (DMSA) is generally easier to administer and better tolerated.

Severe Lead Encephalopathy

Historically and in current specialist practice, severe lead encephalopathy may require combination parenteral chelation.

Dimercaprol (BAL) plus CaNa₂EDTA has traditionally been used for severe lead encephalopathy.

CaNa₂EDTA should not casually be used as unsupervised monotherapy in this setting.

The exact regimen should follow current toxicology/poison-center protocols.

Why BAL Historically Precedes CaNa₂EDTA

Older practice recommends beginning dimercaprol before CaNa₂EDTA in lead encephalopathy.

This approach arose partly from concern about redistribution of lead during EDTA chelation and the possibility of worsening CNS exposure.

Although the evidence base is largely historical, combination therapy remains an established approach for severe encephalopathic lead poisoning.

Succimer

Succimer (DMSA) is an oral chelator used for many cases of lead poisoning when oral treatment is appropriate.

Advantages include:

• Oral administration
• Generally better tolerability
• Less invasive treatment

However, severe encephalopathy requires a different approach and should not be managed simply with oral succimer.

Chelation Is Not Based on Symptoms Alone

The decision to chelate depends on:

• Confirmed venous blood lead concentration
• Symptoms
• Patient age
• Presence of encephalopathy
• Ability to tolerate oral treatment
• Ongoing exposure
• Renal function

Modern blood-lead thresholds and public-health recommendations have changed considerably since older toxicology texts were written.

Historical cutoffs should therefore not be applied automatically.

Blood Lead Level

A venous blood lead level (BLL) is the primary laboratory test used to assess lead exposure.

Capillary screening can be contaminated by environmental lead on the skin, so elevated screening results generally require appropriate venous confirmation.

Treatment decisions should use current age-specific and public-health guidance.

Removing the Source Is Essential

Chelation cannot compensate for continued lead exposure.

Management must identify and eliminate the source, such as:

• Lead-containing paint or dust
• Contaminated soil
• Occupational exposure
• Contaminated traditional remedies
• Certain cosmetics
• Lead-containing cookware or ceramics
• Retained lead-containing foreign material

If exposure continues, blood lead concentrations can rise again despite successful chelation.

Renal Elimination

The lead–EDTA complex is primarily eliminated in urine.

Therefore, renal function is crucial during therapy.

Monitor:

• Creatinine
• Urine output
• Hydration
• Electrolytes
• Urinalysis when appropriate

Significant renal dysfunction complicates therapy and requires specialist management.

Nephrotoxicity

An important adverse effect of CaNa₂EDTA is renal tubular injury.

Risk increases with:

• Excessive exposure to the chelator
• Dehydration
• Preexisting renal impairment
• Prolonged or repeated treatment

Renal injury is often reversible when recognized promptly and treatment is appropriately modified.

Hydration

Adequate hydration and renal perfusion are important during CaNa₂EDTA therapy.

However, fluid administration should be individualized rather than targeting a rigid urine-output number in every patient.

Excessive fluid administration can itself cause complications.

Loss of Essential Metals

CaNa₂EDTA is not perfectly selective for lead.

It can increase urinary loss of other metals, especially:

• Zinc

Other trace-metal effects may also occur.

This becomes particularly relevant during repeated or prolonged chelation.

Other Adverse Effects

Reported effects include:

• Malaise
• Fatigue
• Fever or chills
• Headache
• Myalgia
• Rash
• Nasal symptoms
• Lacrimation
• Urinary frequency
• Glycosuria
• Hypotension

Serious toxicity is more likely with inappropriate formulation, excessive treatment, or impaired renal clearance.

Extravasation

CaNa₂EDTA can cause local tissue injury if it extravasates.

Possible findings include:

• Pain
• Swelling
• Inflammation
• Local calcium deposition or calcification

If extravasation occurs, stop administration through the affected line and manage according to an appropriate extravasation protocol.

Critical Medication Error – Disodium EDTA

One of the most important points in this entire topic is avoiding confusion between:

Calcium disodium EDTA

CaNa₂EDTA

Used for lead chelation.

Disodium EDTA

Na₂EDTA

Can bind calcium aggressively.

Accidental administration of disodium EDTA instead of CaNa₂EDTA can cause:

Rapid hypocalcemia → tetany/seizures → QT abnormalities/dysrhythmias → cardiac arrest

Fatal medication errors have occurred from confusing these formulations.

EDTA Provocation Testing

The older source describes an EDTA provocation test, in which chelator was administered and urinary metal excretion subsequently measured.

This practice is now obsolete.

Provoked urine testing is not recommended for diagnosing lead poisoning or deciding whether chelation is necessary.

Giving a chelator will predictably increase urinary metal excretion, making the resulting measurement difficult or impossible to interpret against normal unprovoked reference ranges.

Do Not Use Chelation as a Diagnostic Test

Modern principle:

Diagnose exposure first → then determine whether chelation is indicated.

Do not administer CaNa₂EDTA merely to see whether urinary lead increases.

Diagnosis should instead rely on:

• Exposure history
• Confirmed venous BLL
• Clinical findings
• Appropriate additional testing

EDTA for Atherosclerosis

EDTA has been promoted in some alternative-medicine settings as a treatment for:

• Atherosclerosis
• Coronary artery disease
• General “detoxification”

These uses are separate from established toxicologic lead chelation.

CaNa₂EDTA should not be regarded as a general-purpose detoxification agent.

Chelation without a legitimate indication can cause significant harm.

Lead-Containing Foreign Bodies

Some lead exposures involve retained material in the gastrointestinal tract or body.

Examples can include:

• Ingested lead objects
• Lead-containing paint chips
• Retained bullets or fragments in selected circumstances

Management depends on:

• Location
• Whether lead is being absorbed
• Blood lead concentration
• Symptoms
• Feasibility and risk of removal

Chelation alone may be insufficient if an ongoing internal source remains.

Pregnancy

The historical pregnancy classification approach in the source is outdated.

Lead crosses the placenta and can harm both the pregnant patient and fetus.

Chelation decisions during pregnancy therefore require individualized specialist assessment based on:

• Severity of maternal toxicity
• BLL
• Gestational stage
• Risks of continued lead exposure
• Risks and benefits of the available chelator

Serious maternal lead toxicity should not go untreated solely because of pregnancy.

Monitoring During CaNa₂EDTA Therapy

Important monitoring includes:

• Clinical neurologic status
• Venous blood lead concentration
• Renal function
• Urine output
• Hydration status
• Electrolytes
• Urinalysis when indicated
• CBC when appropriate
• Evidence of continued environmental exposure

Repeated courses require careful reassessment.

Rebound After Chelation

After chelation ends, BLL can increase again because lead redistributes from tissue and bone stores into blood.

Therefore, follow-up BLL testing is important.

A substantial rise should also prompt investigation for:

• Continued environmental exposure
• Incomplete source removal
• Retained internal lead source

Repeated chelation without eliminating exposure is not an adequate long-term strategy.

Chelation Does Not Reverse All Lead Injury

Lowering the blood lead concentration does not guarantee reversal of established neurologic injury.

This is especially important in children, where chronic lead exposure can affect neurodevelopment.

The best treatment remains:

Prevention and complete removal of the exposure source.

Important Modernization of the Older Source

Several historical recommendations need updating:

• The correct lead-chelating formulation is calcium disodium EDTA (CaNa₂EDTA).
• It must never be confused with disodium EDTA, which can produce fatal hypocalcemia.
• CaNa₂EDTA is mainly used for significant lead poisoning requiring parenteral chelation.
• Oral succimer is preferred for many appropriate non-encephalopathic cases.
• Severe lead encephalopathy requires urgent specialist-directed therapy; BAL plus CaNa₂EDTA remains a traditional parenteral approach.
• Historical fixed BLL cutoffs should not automatically be applied to contemporary patients because lead-management recommendations have evolved.
• CaNa₂EDTA is nephrotoxic and requires renal monitoring.
• Chelation increases loss of essential trace metals, especially zinc.
• EDTA provocation testing is obsolete and should not be used to diagnose metal toxicity.
• Provoked urinary metal concentrations should not be compared with ordinary reference ranges.
• Chelation should not be used as nonspecific “detoxification.”
• Eliminating the lead source is essential; otherwise toxicity can recur.
• BLL may rebound after treatment because of redistribution from tissue stores.
• Pregnancy requires individualized risk-benefit assessment rather than application of an obsolete FDA letter category.
• Exact chelation schedules should follow current toxicology and poison-center guidance rather than historical fixed regimens.

Key Points

• CaNa₂EDTA is a parenteral chelator used primarily for significant lead poisoning.
• Lead displaces calcium from the EDTA complex and is subsequently eliminated as a urinary chelate.
• Calcium disodium EDTA and disodium EDTA are completely different from a safety standpoint.
• Disodium EDTA can cause profound, potentially fatal hypocalcemia.
• Succimer is generally preferred when an appropriate patient can receive oral chelation.
• Severe lead encephalopathy requires urgent specialist management and may require BAL plus CaNa₂EDTA.
• Renal elimination makes kidney function and hydration important during treatment.
• Nephrotoxicity is a major adverse effect of CaNa₂EDTA.
• CaNa₂EDTA can increase zinc and other trace-metal losses.
• EDTA provocation testing is obsolete.
• Chelation should never substitute for identification and elimination of the lead source.
• Blood lead concentrations can rebound after chelation because lead redistributes from tissue and bone.
• Established neurologic injury may not completely reverse even after successful chelation.

Toxicology – Edrophonium

Core Concept

Edrophonium is an ultra-short-acting, reversible acetylcholinesterase inhibitor.

By temporarily preventing acetylcholine breakdown, it increases acetylcholine at:

• Neuromuscular junctions
• Parasympathetic muscarinic synapses
• Autonomic ganglia

Historically, edrophonium was best known for the Tensilon test for myasthenia gravis and for reversal of nondepolarizing neuromuscular blockade.

Its role in modern medicine and toxicology is now very limited. The traditional diagnostic Tensilon test has largely been replaced by safer and more specific testing, and edrophonium is not a routine treatment for neurotoxic snakebite.

Mechanism of Action

Acetylcholinesterase normally hydrolyzes acetylcholine within the synaptic cleft.

Edrophonium reversibly inhibits this enzyme:

AChE inhibition → ↓ acetylcholine breakdown → ↑ synaptic acetylcholine

At the neuromuscular junction, the increased acetylcholine can temporarily improve transmission when postsynaptic nicotinic receptors are incompletely available or competitively blocked.

Rapid, Short-Lived Action

Edrophonium has:

• Very rapid onset
• Very short duration

This historically made it attractive as a diagnostic drug because any improvement or adverse cholinergic effect appeared quickly and generally resolved relatively rapidly.

Its short action also limits its usefulness as sustained therapy.

Historical Myasthenia Gravis Testing

Myasthenia gravis is an autoimmune disorder of neuromuscular transmission, most commonly involving antibodies against components of the postsynaptic neuromuscular junction.

Typical manifestations include:

• Ptosis
• Diplopia
• Bulbar weakness
• Fatigable skeletal-muscle weakness
• Respiratory weakness in severe disease

Historically, transient improvement after edrophonium supported the diagnosis.

Why the Tensilon Test Is Largely Obsolete

Edrophonium testing has major limitations:

• False-positive and false-negative responses can occur.
• Interpretation can be subjective.
• Bradycardia and other cholinergic complications can occur.
• More specific diagnostic methods are now available.

Modern evaluation may include:

• Acetylcholine-receptor antibodies
• MuSK antibodies
• Other relevant antibody testing
• Repetitive nerve stimulation
• Single-fiber electromyography
• Clinical neurologic assessment

Therefore, the historical Tensilon test is no longer a routine first-line diagnostic test.

Nondepolarizing Neuromuscular Blockade

Nondepolarizing neuromuscular blockers competitively antagonize nicotinic acetylcholine receptors at the neuromuscular junction.

Increasing acetylcholine can compete with these drugs.

Thus:

Edrophonium → ↑ ACh → competition with nondepolarizing blocker → improved neuromuscular transmission

This explains its historical use for postoperative reversal.

Modern Reversal of Neuromuscular Blockade

Edrophonium is now rarely used for this purpose.

Modern anesthesia more commonly uses:

• Neostigmine for appropriate nondepolarizing blockade
• Sugammadex for selected aminosteroid neuromuscular blockers such as rocuronium and vecuronium

Choice depends on the blocker, depth of blockade, patient characteristics, and available agents.

Snakebite – Historical Role

Older literature described edrophonium or other acetylcholinesterase inhibitors for neuroparalytic snake envenomation.

The theoretical mechanism is:

More acetylcholine at the neuromuscular junction → partial competition against postsynaptic neurotoxin-mediated receptor blockade

This approach can sometimes temporarily improve weakness caused by certain postsynaptic neurotoxins.

Why Response Depends on Venom Mechanism

Snake neurotoxins do not all work at the same site.

Postsynaptic Neurotoxins

These interfere with nicotinic acetylcholine receptors.

Increasing acetylcholine may sometimes improve neuromuscular transmission.

Presynaptic Neurotoxins

These damage or disrupt acetylcholine release from the nerve terminal.

If acetylcholine is not being released adequately, simply preventing its breakdown is much less useful.

Therefore:

A response to an acetylcholinesterase inhibitor depends strongly on the venom’s neurotoxic mechanism.

Modern Neurotoxic Snakebite Management

Management centers on:

• Airway assessment
• Close respiratory monitoring
• Early ventilatory support when necessary
• Appropriate species/regional antivenom
• General supportive care

Anticholinesterase therapy is not a substitute for antivenom or mechanical ventilation.

If considered at all, it should be used only in selected neurotoxic envenomations under specialist guidance.

Cholinergic Effects

Because edrophonium raises acetylcholine concentrations, excessive activity can produce a cholinergic syndrome.

Muscarinic manifestations may include:

• Salivation
• Lacrimation
• Sweating
• Nausea
• Vomiting
• Abdominal cramping
• Diarrhea
• Bronchial secretions
• Bronchoconstriction
• Bradycardia
• Hypotension

Pulmonary secretions and bradycardia are particularly important acute complications.

Nicotinic Effects

Excessive acetylcholine at the neuromuscular junction can eventually impair rather than improve transmission.

Possible manifestations include:

• Fasciculations
• Muscle weakness
• Respiratory muscle weakness

Thus, excessive acetylcholinesterase inhibition can paradoxically worsen neuromuscular function.

Respiratory Failure

Respiratory deterioration following edrophonium can result from:

• Bronchorrhea
• Bronchospasm
• Upper-airway secretions
• Respiratory muscle weakness
• Progression of the underlying neuromuscular disorder

In snakebite, this creates an important diagnostic problem because venom-induced paralysis and excessive cholinergic activity may coexist.

Airway and ventilation take priority over trying to distinguish them at the bedside.

Bradycardia

Edrophonium can increase parasympathetic activity at the heart.

This can cause:

• Sinus bradycardia
• AV conduction slowing
• Hypotension
• Rarely profound bradycardia or cardiac arrest

Continuous ECG monitoring is appropriate when edrophonium is used in a setting where significant cardiovascular effects are possible.

Atropine

Atropine antagonizes the muscarinic effects of excessive acetylcholine.

It can therefore counter manifestations such as:

• Severe bradycardia
• Excessive bronchial secretions
• Other important muscarinic effects

However:

Atropine does not reverse nicotinic skeletal-muscle weakness.

This distinction is important in both cholinesterase-inhibitor toxicity and neurotoxic snakebite.

Organophosphate and Carbamate Poisoning

Edrophonium should not be used to treat these poisonings.

Organophosphates and carbamates already inhibit acetylcholinesterase.

Adding another acetylcholinesterase inhibitor can worsen:

• Bronchorrhea
• Bronchospasm
• Bradycardia
• Secretions
• Cholinergic neuromuscular dysfunction

For significant organophosphate poisoning, modern therapy instead centers on:

• Airway and ventilation
• Atropine
• Pralidoxime when appropriate
• Benzodiazepines for seizures

Interaction With Other Anticholinesterases

Additive cholinergic effects can occur with agents such as:

• Neostigmine
• Pyridostigmine
• Physostigmine
• Other acetylcholinesterase inhibitors

Excessive combined activity can produce a cholinergic crisis.

Cardiac Disease and Drug Interactions

Patients taking medications that already slow cardiac conduction may be more vulnerable to clinically important bradycardia.

Examples include selected:

• Beta blockers
• Calcium channel blockers
• Digoxin

The interaction is primarily important because several mechanisms may simultaneously depress heart rate or AV conduction.

Myasthenic vs Cholinergic Crisis

Historically, edrophonium was sometimes used in an attempt to distinguish these syndromes.

Myasthenic Crisis

Severe weakness due to inadequate neuromuscular transmission from myasthenia gravis.

Cholinergic Crisis

Weakness resulting from excessive acetylcholinesterase inhibition.

The historical idea was that edrophonium might briefly improve myasthenic weakness while worsening cholinergic weakness.

In modern practice, this approach is generally avoided because it can be unreliable and potentially dangerous.

Respiratory support and specialist evaluation are more important.

Hypotension

Hypotension can accompany excessive cholinergic activity, especially when associated with bradycardia.

Management focuses on:

• Airway and breathing
• Appropriate IV fluid resuscitation
• Treatment of severe muscarinic effects
• Vasopressor support when necessary

The older routine recommendation for Trendelenburg positioning is obsolete and should not substitute for proper shock management.

Seizures

Seizures are not a typical therapeutic effect of edrophonium but can occur in severe toxic states or from other underlying causes.

If seizures occur:

Benzodiazepines are generally first-line therapy for toxicologic seizures.

Routine phenytoin is not the preferred general second-line strategy for toxin-induced seizures.

Pregnancy

The historical FDA pregnancy Category C designation is obsolete.

Use during pregnancy should depend on:

• Clinical necessity
• Maternal condition
• Availability of safer or better-established alternatives

For life-threatening neuromuscular or toxicologic emergencies, maternal stabilization remains the priority.

Monitoring

When edrophonium is used, monitor:

• Airway
• Respiratory effort
• Bronchial secretions
• Oxygenation and ventilation
• Heart rate
• ECG
• Blood pressure
• Skeletal-muscle strength
• Signs of excessive cholinergic activity

In neurotoxic snakebite, serial assessment of respiratory muscle function is particularly important.

Important Modernization of the Older Source

Several historical recommendations require substantial revision:

• Edrophonium is a short-acting reversible acetylcholinesterase inhibitor.
• The traditional Tensilon test for myasthenia gravis is largely obsolete.
• Modern myasthenia diagnosis relies more heavily on antibody testing, electrodiagnostic studies, and clinical assessment.
• Edrophonium is rarely used for reversal of postoperative neuromuscular blockade; neostigmine and sugammadex have largely replaced it in modern anesthesia practice.
• Anticholinesterase therapy is not routine treatment for neurotoxic snakebite.
• Selected postsynaptic neurotoxic envenomations may respond to an acetylcholinesterase inhibitor, whereas presynaptic neurotoxicity generally responds poorly.
• Appropriate antivenom and respiratory support remain the central treatments for serious neurotoxic snakebite.
• Edrophonium can itself produce dangerous cholinergic toxicity, including bronchorrhea, bradycardia, hypotension, and respiratory weakness.
• Atropine reverses dangerous muscarinic effects but does not correct nicotinic paralysis.
• Edrophonium should not be added to organophosphate or carbamate poisoning.
• Trendelenburg positioning is not modern definitive treatment for toxicologic hypotension.
• Historical fixed dosing regimens should not be generalized to contemporary snakebite management.

Key Points

• Edrophonium is an ultra-short-acting reversible acetylcholinesterase inhibitor.
• It increases acetylcholine at cholinergic synapses and the neuromuscular junction.
• Its historical diagnostic use in myasthenia gravis has largely been replaced by modern antibody and electrophysiologic testing.
• Its historical role in postoperative reversal has also largely been replaced by other agents.
• Edrophonium has only a limited, specialist-directed role in selected neurotoxic snake envenomations.
• Postsynaptic neurotoxic blockade is more likely to respond than presynaptic neurotoxicity.
• Antivenom and respiratory support are more important than anticholinesterase therapy in serious snakebite.
• Excess edrophonium can cause a cholinergic syndrome.
• Dangerous effects include bronchial secretions, bronchospasm, bradycardia, hypotension, and respiratory weakness.
• Atropine treats muscarinic toxicity but not nicotinic skeletal-muscle paralysis.
• Edrophonium can worsen organophosphate or carbamate poisoning.
• Airway and ventilation are the priorities whenever neuromuscular respiratory failure is developing.

Toxicology – Digoxin Immune Fab

Core Concept

Digoxin immune Fab is the specific antidote for severe poisoning by digoxin and related cardiac glycosides.

It consists of antibody Fab fragments with high affinity for digoxin. After administration, Fab binds circulating free digoxin, producing an inactive complex and shifting additional digoxin away from its tissue receptor sites.

Modern products may differ by region; the historical brand Digibind is no longer the only relevant formulation.

Mechanism of Digoxin Toxicity

Digoxin inhibits the cellular:

Na⁺/K⁺-ATPase

This increases intracellular sodium and indirectly increases intracellular calcium in cardiac cells.

At therapeutic concentrations this contributes to:

• Increased cardiac contractility
• Increased vagal tone
• Slower AV nodal conduction

In overdose, excessive Na⁺/K⁺-ATPase inhibition causes widespread electrical instability.

Why Hyperkalemia Occurs

Na⁺/K⁺-ATPase normally moves potassium into cells.

In severe acute digoxin poisoning:

Na⁺/K⁺-ATPase inhibition → impaired cellular K⁺ uptake → extracellular K⁺ rises

Therefore, hyperkalemia can be an important marker of severe acute toxicity.

This differs from chronic toxicity, where potassium may be normal or low because of factors such as diuretic therapy.

Mechanism of Digoxin Immune Fab

Fab fragments bind free digoxin with greater affinity than digoxin has for its tissue receptors.

This produces:

Digoxin + Fab → digoxin–Fab complex

As circulating free digoxin falls, digoxin dissociates from Na⁺/K⁺-ATPase and redistributes into the bloodstream, where additional Fab binds it.

The result is:

• Rapid reduction in free active digoxin
• Reversal of Na⁺/K⁺-ATPase inhibition
• Improvement in cardiac toxicity
• Improvement of digoxin-associated hyperkalemia

Major Indications

Digoxin immune Fab should be strongly considered for life-threatening or clinically significant cardiac glycoside toxicity, particularly with:

• Hemodynamic instability
• Severe hypotension or shock
• Clinically important bradycardia
• High-grade AV block
• Dangerous ventricular dysrhythmias
• Cardiac arrest
• Significant acute digoxin-associated hyperkalemia
• Rapidly progressive severe toxicity

Treatment decisions should be driven primarily by the patient’s clinical condition rather than an isolated digoxin concentration.

Acute Digoxin Poisoning

Acute overdose commonly causes:

• Nausea
• Vomiting
• Abdominal discomfort
• Hyperkalemia
• Bradycardia
• AV conduction abnormalities
• Ventricular ectopy or dysrhythmias
• Hypotension
• Altered mental status in severe cases

Severe hyperkalemia in acute poisoning reflects substantial Na⁺/K⁺-ATPase inhibition and is an important marker of systemic toxicity.

Chronic Digoxin Toxicity

Chronic toxicity often occurs in patients already receiving therapeutic digoxin.

Predisposing factors include:

• Renal impairment
• Advanced age
• Dehydration
• Drug interactions
• Electrolyte disturbances

Manifestations may be less dramatic and include:

• Anorexia
• Nausea
• Weakness
• Confusion or delirium
• Visual disturbances
• Bradycardia
• AV block
• Atrial or ventricular dysrhythmias

Renal Function

Digoxin is substantially eliminated through the kidneys.

Reduced renal function can therefore:

• Prolong digoxin elimination
• Increase the risk of chronic accumulation
• Prolong toxicity

Renal dysfunction also slows elimination of digoxin–Fab complexes after antidotal treatment.

Serum Digoxin Concentration

A digoxin concentration can support diagnosis but must be interpreted carefully.

Important factors include:

• Timing of the sample
• Acute versus chronic exposure
• Renal function
• Clinical findings
• Electrolytes

A number without clinical context can be misleading.

Early Levels After Acute Ingestion

After an acute oral ingestion, digoxin requires several hours to distribute from plasma into tissues.

Therefore:

A concentration obtained during the early distribution phase can appear very high without accurately reflecting the final tissue burden.

Early concentrations should not automatically be used for Fab calculations.

When the patient is critically ill, however, treatment should not be delayed simply to wait for a later concentration.

Digoxin Levels After Fab

This is one of the most important pitfalls.

After digoxin immune Fab is administered, many routine digoxin assays measure:

Fab-bound digoxin + free digoxin

Consequently, the reported “total digoxin” concentration may become extremely high even though active free digoxin has fallen dramatically.

Therefore:

Routine total serum digoxin concentrations after Fab are generally not useful for judging treatment response.

Clinical response, ECG findings, potassium, and hemodynamics are much more useful.

Free Digoxin Assays

Specialized assays capable of measuring unbound/free digoxin may occasionally provide useful information.

However, these tests are not routinely available and are generally unnecessary for ordinary emergency management.

Potassium After Fab

As Na⁺/K⁺-ATPase function recovers, potassium moves back into cells.

Therefore:

Serum potassium can fall rapidly after successful Fab treatment.

Monitor potassium closely.

Hypokalemia can develop, particularly when the patient was potassium-depleted before the poisoning.

Hyperkalemia Management

In severe digoxin poisoning, the most important treatment for digoxin-mediated hyperkalemia is:

Digoxin immune Fab

Fab addresses the underlying Na⁺/K⁺-ATPase inhibition rather than merely shifting potassium temporarily.

Other emergency hyperkalemia measures may still be needed according to the patient’s condition.

Calcium and Digoxin Toxicity

Older teaching warned that IV calcium in digoxin poisoning could cause irreversible contraction or a so-called “stone heart.”

Modern evidence does not support an absolute prohibition.

Therefore:

• Calcium is not absolutely contraindicated when a patient with digoxin toxicity has life-threatening hyperkalemic cardiac instability.
• Fab remains the definitive therapy for severe digoxin poisoning.
• Management should be individualized in consultation with toxicology/poison-center expertise when possible.

Dysrhythmias

Digoxin can produce an unusually broad range of rhythm disturbances because it alters:

• Automaticity
• AV nodal conduction
• Refractoriness
• Intracellular calcium handling

Possible findings include:

• Sinus bradycardia
• AV block
• Junctional rhythms
• Premature ventricular beats
• Ventricular tachycardia
• Bidirectional ventricular tachycardia
• Atrial tachycardia with AV block

The combination of increased automaticity plus impaired AV conduction is particularly characteristic.

Fab and Cardiac Rhythm

Successful neutralization can rapidly improve:

• Bradycardia
• AV conduction abnormalities
• Ventricular dysrhythmias
• Hypotension
• Hyperkalemia

However, the patient still requires continuous monitoring because underlying cardiac disease and other electrolyte abnormalities may remain.

Loss of Therapeutic Digoxin Effect

Fab does not distinguish between “toxic” digoxin and digoxin that was providing a desired therapeutic effect.

Neutralization may therefore reveal or worsen the patient’s underlying condition.

Possible consequences include:

• Faster ventricular response in atrial fibrillation
• Worsening heart failure
• Loss of desired inotropic effect

This possibility should be anticipated, but it should not prevent adequate reversal of genuinely life-threatening toxicity.

Partial vs Full Neutralization

Older protocols sometimes emphasized deliberately leaving a therapeutic amount of digoxin unbound.

Modern practice is more clinically individualized.

In life-threatening poisoning, the priority is adequate neutralization of dangerous toxicity.

In less severe chronic toxicity, smaller or titrated Fab administration may sometimes be appropriate to avoid unnecessary complete reversal.

Fab Dosing Principles

The required amount can be estimated from:

• A reliable known digoxin exposure
• A properly timed serum digoxin concentration and patient weight

However, exact calculations are not always necessary or reliable.

In unstable poisoning, empiric Fab administration based on severity may be appropriate.

Historical fixed vial counts should not automatically replace current product-specific recommendations and poison-center guidance.

Other Cardiac Glycosides

Digoxin immune Fab can cross-react with several naturally occurring cardiac glycosides.

Potential exposures include:

• Oleander
• Yellow oleander
• Foxglove
• Lily of the valley
• Certain other cardiac-glycoside-containing plants

Severe poisoning can resemble digoxin toxicity.

Toad Toxins

Some toads produce bufadienolide cardiac glycosides.

These can inhibit Na⁺/K⁺-ATPase and produce:

• Bradycardia
• AV block
• Ventricular dysrhythmias
• Hyperkalemia
• Cardiovascular collapse

Digoxin immune Fab has been successfully used in some severe cases.

Because binding affinity varies among non-digoxin glycosides, treatment requirements can be less predictable than for pharmaceutical digoxin.

Traditional or Herbal Products

Some traditional remedies or products may contain cardiac glycosides derived from:

• Plants
• Toad secretions
• Other biologic sources

When a patient develops a compatible cardiac-glycoside syndrome after such an exposure, Fab may be considered even when the precise glycoside is unknown.

Cross-Reactivity With Digoxin Assays

Some non-digoxin cardiac glycosides can cross-react with laboratory digoxin immunoassays.

Therefore, a detectable “digoxin” concentration after plant or animal glycoside exposure may support the diagnosis but:

The numerical value may not accurately represent the amount or severity of the non-digoxin glycoside exposure.

Clinical findings remain central.

Endogenous Digoxin-Like Substances

Some assays can detect endogenous substances with digoxin-like immunoreactivity.

These have historically been reported in circumstances such as:

• Neonatal physiology
• Pregnancy
• Renal dysfunction
• Hepatic disease

Therefore, an unexpected low-level digoxin result should always be interpreted in context rather than automatically diagnosing poisoning.

Allergic Reactions

Digoxin immune Fab is generally well tolerated.

Hypersensitivity reactions are uncommon but can include:

• Rash
• Urticaria
• Wheezing
• Hypotension
• Anaphylaxis

Emergency treatment for anaphylaxis should be available during administration.

A remote history of wool sensitivity alone does not necessarily establish clinically important allergy to Fab.

Renal Failure After Fab

The digoxin–Fab complex is normally eliminated predominantly through the kidneys.

In severe renal impairment:

• Complex elimination is delayed.
• Total measured digoxin may remain elevated for prolonged periods.
• Clinical monitoring may need to continue longer.

Historical reports have raised concern about delayed recurrence as complexes persist, although clinically significant rebound toxicity is uncommon after adequate neutralization.

Hemodialysis

Digoxin itself has a large volume of distribution and is poorly removed by conventional hemodialysis.

Digoxin–Fab complexes are also not efficiently managed by routine dialysis.

Therefore:

Hemodialysis is not an effective primary method for removing digoxin and should not replace Fab.

Dialysis may still be required for an independent renal or metabolic indication.

Pregnancy

The historical FDA pregnancy Category C system is obsolete.

Life-threatening maternal digoxin toxicity threatens both mother and fetus.

Therefore:

Digoxin immune Fab should not be withheld when clinically indicated during pregnancy.

Maternal stabilization is the priority.

Monitoring

Patients with significant cardiac glycoside poisoning should have:

• Continuous ECG monitoring
• Frequent blood pressure assessment
• Serial potassium
• Magnesium
• Renal function
• Clinical perfusion assessment
• Mental-status monitoring
• Appropriately timed pre-Fab digoxin concentration when useful

After Fab, follow the patient, not the total digoxin number.

Important Modernization of the Older Source

Several points require updating:

• Digoxin immune Fab remains the specific antidote for severe cardiac glycoside poisoning.
• Life-threatening cardiovascular toxicity is a stronger reason for Fab than an isolated serum digoxin concentration.
• Hyperkalemia is particularly important in acute digoxin poisoning.
• Early post-ingestion digoxin concentrations can be misleading because distribution is incomplete.
• Treatment of an unstable patient should not be delayed while waiting for a post-distribution level.
• After Fab, routine total digoxin assays become misleading because they often measure Fab-bound digoxin.
• Potassium may fall rapidly after successful reversal and requires close monitoring.
• The historical “stone heart” concern does not make calcium absolutely contraindicated in life-threatening hyperkalemia associated with digoxin toxicity.
• Hemodialysis does not effectively remove digoxin and is not a substitute for Fab.
• Fab can be effective against selected plant and toad cardiac glycosides, although the required degree of neutralization is less predictable.
• Older universal empiric vial counts should not automatically be applied; modern therapy uses product-specific guidance and clinical severity.
• Deliberately incomplete reversal may occasionally be reasonable in selected chronic toxicity, but adequate reversal takes priority in life-threatening poisoning.
• Historical FDA pregnancy categories are obsolete.

Key Points

• Digoxin immune Fab is the definitive antidote for severe digoxin toxicity.
• Fab binds free digoxin and promotes redistribution away from Na⁺/K⁺-ATPase.
• Important indications include unstable bradycardia, serious AV block, ventricular dysrhythmias, shock, cardiac arrest, and significant acute digoxin-associated hyperkalemia.
• Acute poisoning commonly causes GI symptoms, hyperkalemia, and cardiovascular toxicity.
• Chronic toxicity is strongly influenced by renal function and drug interactions.
• A digoxin concentration obtained too early after acute ingestion may be misleading.
• After Fab, total serum digoxin concentrations are generally uninterpretable for treatment response.
• Follow ECG, hemodynamics, potassium, renal function, and clinical improvement instead.
• Potassium can fall rapidly after Fab.
• Fab can eliminate beneficial therapeutic digoxin effects, potentially revealing atrial fibrillation or heart failure.
• Digoxin is poorly dialyzable.
• Calcium is no longer considered absolutely forbidden in digoxin-associated hyperkalemia.
• Fab may also neutralize selected oleander, foxglove, and toad-derived cardiac glycosides.
• In life-threatening poisoning, clinical severity—not a rigid concentration or historical vial formula—should drive urgent antidotal treatment.

Toxicology – Dextrose (Glucose)

Core Concept

Dextrose is D-glucose, the principal carbohydrate used intravenously to rapidly correct clinically important hypoglycemia.

Its major toxicologic roles are:

• Treatment of symptomatic hypoglycemia
• Treatment of documented severe hypoglycemia
• Prevention/treatment of hypoglycemia during insulin therapy for hyperkalemia
• Continuous glucose support in selected poisonings that cause recurrent hypoglycemia

Modern practice favors measuring bedside glucose rapidly rather than routinely giving empiric dextrose to every patient with altered mental status.

Mechanism of Action

Glucose is a major metabolic fuel.

After cellular uptake it provides substrate for:

• Glycolysis
• Oxidative metabolism
• ATP production

The brain is particularly dependent on circulating glucose, so severe hypoglycemia can rapidly cause neurologic dysfunction.

Clinical Effects of Hypoglycemia

Hypoglycemia activates both autonomic and neuroglycopenic responses.

Autonomic Features

May include:

• Sweating
• Tremor
• Palpitations
• Tachycardia
• Hunger
• Anxiety

Neuroglycopenic Features

May include:

• Confusion
• Behavioral change
• Weakness
• Visual disturbance
• Altered mental status
• Seizures
• Coma

Severe or prolonged hypoglycemia can cause permanent neurologic injury.

Do Not Rely on One Universal Glucose Threshold

The older source uses a glucose concentration below 60 mg/dL as a fixed treatment threshold.

Modern interpretation is more clinical.

Treatment depends on:

• Glucose concentration
• Symptoms
• Patient age
• Diabetes history
• Underlying cause
• Ability to take oral carbohydrate safely

Clinically significant symptomatic hypoglycemia warrants prompt correction.

Relative Hypoglycemia

People with chronically elevated glucose concentrations may sometimes develop adrenergic symptoms when glucose falls rapidly toward a concentration that would normally be considered acceptable.

This is sometimes called relative hypoglycemia.

It should be distinguished from true biochemical hypoglycemia.

Toxicologic Causes of Hypoglycemia

Important causes include:

• Insulin
• Sulfonylureas
• Meglitinides
• Ethanol, particularly with fasting or poor nutritional reserves
• Salicylates
• Certain beta blockers
• Quinine
• Severe hepatic-toxicant injury
• Selected other medications

The cause determines whether glucose replacement alone is sufficient.

Insulin Poisoning

Excess insulin drives glucose into cells and suppresses endogenous glucose production.

This can produce:

• Recurrent hypoglycemia
• Hypokalemia
• Neurologic dysfunction
• Seizures
• Coma

Treatment centers on glucose replacement and repeated glucose monitoring.

Recurrent Hypoglycemia After Insulin

A single dextrose treatment may temporarily normalize glucose while excessive insulin activity persists.

Therefore:

Normal glucose after one treatment does not mean the poisoning has resolved.

Some patients require prolonged carbohydrate intake or continuous IV dextrose with careful titration.

Sulfonylurea Poisoning

Sulfonylureas stimulate pancreatic insulin secretion.

This can produce prolonged or recurrent hypoglycemia.

Dextrose corrects the immediate low glucose but can also stimulate further insulin secretion.

The cycle can become:

Hypoglycemia → dextrose → glucose rises → additional insulin secretion → recurrent hypoglycemia

Octreotide in Sulfonylurea Poisoning

For recurrent sulfonylurea-induced hypoglycemia, octreotide is an important antidotal treatment because it suppresses pancreatic insulin secretion.

Thus:

Dextrose corrects the glucose deficit.

Octreotide helps prevent recurrent insulin-mediated hypoglycemia.

Repeated large dextrose boluses alone are often an inadequate strategy for significant sulfonylurea poisoning.

Oral Glucose

If the patient is:

• Awake
• Cooperative
• Able to swallow
• Able to protect the airway

mild hypoglycemia can often be treated with oral carbohydrate.

IV therapy is preferred when there is:

• Significant altered consciousness
• Seizure
• Inability to swallow
• Severe hypoglycemia
• Need for rapid reliable correction

IV Dextrose Concentrations

Common preparations include:

• D5W
• D10W
• More concentrated dextrose solutions

Highly concentrated preparations provide substantial glucose in a small volume but are also hyperosmolar and irritating to veins and tissues.

Modern emergency practice often uses less concentrated solutions when feasible, especially in children.

Why Concentrated Dextrose Requires Caution

Very concentrated dextrose can cause:

• Venous irritation
• Phlebitis
• Pain
• Tissue injury after extravasation
• Abrupt hyperglycemia

Peripheral IV patency should therefore be confirmed before administration.

Pediatric Hypoglycemia

Older protocols frequently used highly concentrated dextrose preparations in children.

Modern pediatric practice generally favors less concentrated dextrose solutions, particularly in infants and young children, because concentrated solutions are markedly hyperosmolar and increase the risk of tissue injury and excessive glucose shifts.

Treatment should be weight-based and guided by current pediatric emergency protocols.

Neonates and Infants

Young infants have:

• Smaller glycogen reserves
• High metabolic requirements
• Greater vulnerability to recurrent hypoglycemia

They therefore require careful serial glucose monitoring after initial correction.

Altered Mental Status

Older emergency practice sometimes used empiric dextrose as part of a universal “coma cocktail.”

Modern practice favors:

Rapid point-of-care glucose measurement → treat if hypoglycemic

because bedside glucose testing is generally available within moments.

Dextrose should not routinely be administered to a patient who is already known to be euglycemic or hyperglycemic.

If Glucose Cannot Be Measured Promptly

If a patient has severe altered mental status, seizure, or coma and hypoglycemia is strongly suspected but glucose testing is temporarily unavailable, treatment should not be delayed when the risk of untreated hypoglycemia is substantial.

The principle is:

Measure immediately when possible; treat immediately when necessary.

Failure to Improve After Dextrose

Correction of hypoglycemia without neurologic improvement should prompt reconsideration of the diagnosis.

Other causes of altered mental status include:

• Opioid toxicity
• Sedative poisoning
• Stroke
• Seizure/postictal state
• Hypoxia
• Hypercapnia
• Electrolyte disturbance
• CNS infection
• Head injury
• Other toxic syndromes

Dextrose is not a nonspecific treatment for coma.

Thiamine and Glucose

Thiamine is an essential cofactor in carbohydrate metabolism.

Patients with severe thiamine deficiency—particularly those with significant malnutrition—may be at risk for Wernicke encephalopathy.

However, an important modern principle is:

Do not delay emergency glucose treatment in a hypoglycemic patient while waiting to administer thiamine.

When thiamine deficiency is suspected, give thiamine promptly, but glucose takes priority when clinically significant hypoglycemia is present.

Ethanol-Associated Hypoglycemia

Ethanol metabolism alters hepatic redox balance and inhibits gluconeogenesis.

Hypoglycemia is particularly likely in:

• Children
• Prolonged fasting
• Malnutrition
• Depleted glycogen stores
• Chronic heavy alcohol use

Glucose should be measured in patients with significant ethanol intoxication and altered consciousness.

Dextrose in Hyperkalemia

Dextrose does not independently constitute the principal potassium-shifting treatment.

Instead, it is commonly administered with insulin.

Insulin stimulates cellular potassium uptake, lowering extracellular potassium concentration.

Dextrose is generally provided to reduce the risk of insulin-induced hypoglycemia when appropriate.

Hyperkalemia – Different Treatment Goals

Management can be understood as three separate objectives:

1. Stabilize the myocardium

→ IV calcium when indicated

2. Shift potassium into cells

→ Insulin is a major therapy; glucose is given as appropriate to prevent hypoglycemia

3. Remove potassium from the body

→ Renal elimination, selected potassium-binding therapies, or dialysis depending on severity and cause

Dextrose itself does not remove potassium from the body.

Glucose Monitoring After Insulin for Hyperkalemia

Hypoglycemia can occur hours after insulin administration, particularly in patients with:

• Renal impairment
• Lower baseline glucose
• Low body mass
• Limited nutritional reserves

Therefore, glucose should be monitored serially after insulin-based hyperkalemia therapy.

A normal glucose immediately after treatment does not eliminate later risk.

Dextrose Is Not Always Required Before Insulin

The older source describes a fixed insulin-plus-dextrose combination.

Modern therapy is more individualized.

If the patient is already significantly hyperglycemic, clinicians may modify initial glucose supplementation while still monitoring closely for later hypoglycemia.

The goal is safe potassium shifting without unnecessary hyperglycemia.

Adverse Effects

Important complications include:

• Hyperglycemia
• Hypokalemia
• Phlebitis
• Extravasation injury
• Fluid overload with large-volume dilute solutions
• Hyperosmolar complications with excessive administration

These risks become more important with prolonged or poorly monitored infusions.

Hypokalemia

Glucose administration stimulates endogenous insulin secretion, while administered insulin directly drives potassium intracellularly.

Consequently, potassium can fall during treatment.

Monitor potassium particularly when:

• Baseline potassium is low
• Large glucose loads are required
• Insulin poisoning is present
• Prolonged dextrose infusion is necessary

Hyperglycemia

Overtreatment can produce marked hyperglycemia.

Potential consequences include:

• Osmotic diuresis
• Dehydration
• Electrolyte abnormalities
• Increased serum osmolality

The objective is adequate euglycemia, not intentionally producing sustained marked hyperglycemia.

Fluid Overload

Large volumes of dilute dextrose solutions can contribute to volume overload.

This is especially relevant in patients with:

• Heart failure
• Renal impairment
• Critical illness requiring substantial IV fluids

Concentration and infusion strategy should therefore be individualized.

Extravasation

Concentrated dextrose is hyperosmolar and can damage tissues if it leaves the vein.

Possible manifestations include:

• Pain
• Swelling
• Local inflammation
• Tissue injury

If extravasation is suspected:

• Stop administration through the affected line.
• Assess the site.
• Follow the appropriate extravasation protocol.

Stroke and Dextrose

The older source emphasizes concern that hyperglycemia may worsen neurologic outcomes after stroke.

The practical modern approach is simpler:

Check glucose rapidly in suspected stroke because both hypoglycemia and hyperglycemia matter.

Hypoglycemia can closely mimic stroke and should be corrected promptly.

Routine dextrose is unnecessary when glucose is normal.

Prophylactic Dextrose in Sulfonylurea Exposure

An asymptomatic patient with a sulfonylurea exposure should not automatically receive repeated prophylactic glucose merely to prevent a possible future low value.

Unnecessary glucose can stimulate insulin release and complicate assessment.

Instead:

• Monitor glucose appropriately.
• Treat actual hypoglycemia.
• Use octreotide when recurrent sulfonylurea-mediated hypoglycemia warrants it.

Stopping a Dextrose Infusion

When prolonged dextrose support has been necessary, clinicians should ensure that glucose remains stable after the infusion is reduced or stopped.

This is especially important after:

• Long-acting insulin exposure
• Large insulin overdose
• Sulfonylurea poisoning
• Other persistent hypoglycemic agents

The observation period depends on the toxicant’s pharmacokinetics rather than a universal fixed duration.

Monitoring

Depending on the situation, monitor:

• Serial bedside glucose
• Mental status
• Potassium
• Other electrolytes
• Renal function
• IV site
• Fluid balance
• Recurrence of hypoglycemic symptoms

The frequency of glucose checks should reflect the severity and expected duration of the causative exposure.

Important Modernization of the Older Source

Several recommendations require updating:

• Routine empiric dextrose for every patient with altered mental status has largely been replaced by rapid bedside glucose testing.
• Treatment should not depend on a universal glucose cutoff; symptoms and clinical context matter.
• Highly concentrated dextrose is no longer automatically preferred for all adults or children.
• Pediatric practice generally favors less concentrated preparations to reduce hyperosmolar and extravasation injury.
• Glucose should never be delayed while waiting for thiamine in a genuinely hypoglycemic patient.
• Sulfonylurea-induced recurrent hypoglycemia should not be managed with repeated dextrose alone; octreotide is an important therapy.
• In hyperkalemia, insulin—not dextrose—is responsible for the major intracellular potassium shift.
• Dextrose accompanying insulin is primarily used to prevent or treat hypoglycemia.
• Glucose monitoring must continue after insulin treatment because delayed hypoglycemia can occur.
• Patients who are already hyperglycemic may not require the same initial glucose supplementation used in euglycemic patients.
• The goal of treatment is restoration and maintenance of safe glucose concentrations, not routine sustained hyperglycemia.

Key Points

• Dextrose is D-glucose and is the primary rapid treatment for clinically significant hypoglycemia.
• Severe hypoglycemia can cause seizures, coma, and permanent neurologic injury.
• Toxicologic causes include insulin, sulfonylureas, meglitinides, ethanol, salicylates, and selected other drugs.
• A single dextrose treatment may not prevent recurrent hypoglycemia.
• Insulin overdose may require prolonged glucose support and close monitoring.
• Sulfonylurea poisoning can recur after dextrose because glucose stimulates additional insulin secretion.
• Octreotide is important for recurrent sulfonylurea-induced hypoglycemia.
• Modern evaluation of unexplained altered mental status emphasizes rapid bedside glucose measurement rather than automatic empiric dextrose.
• Do not delay glucose for thiamine when true hypoglycemia requires urgent treatment.
• In hyperkalemia, insulin shifts potassium intracellularly; dextrose mainly protects against insulin-induced hypoglycemia.
• Calcium stabilizes the myocardium in severe hyperkalemia but does not lower potassium.
• Highly concentrated dextrose can cause phlebitis and serious extravasation injury.
• Children, particularly infants, generally receive less concentrated preparations.
• Monitor for recurrent hypoglycemia, hyperglycemia, potassium changes, fluid complications, and IV-site injury.

Toxicology – Deferoxamine

Core Concept

Deferoxamine (DFO) is a parenteral chelating agent used primarily for clinically significant iron poisoning and for selected chronic iron- or aluminum-overload states.

In acute toxicology, its major role is:

Severe acute iron poisoning → deferoxamine chelation

It binds toxic circulating and tissue-accessible ferric iron (Fe³⁺), forming a less toxic, water-soluble complex called ferrioxamine.

Why Iron Becomes Toxic

Iron is normally safely incorporated into proteins such as:

• Hemoglobin
• Ferritin
• Transferrin
• Hemosiderin
• Iron-containing enzymes

After a sufficiently large acute exposure, normal binding capacity can become overwhelmed.

Excess free iron can then cause:

• Direct gastrointestinal corrosive injury
• Oxidative stress and free-radical formation
• Mitochondrial dysfunction
• Cellular injury
• Vasodilation and shock
• Metabolic acidosis
• Hepatic injury

Mechanism of Deferoxamine

Deferoxamine has a high affinity for ferric iron.

The basic reaction is:

Deferoxamine + Fe³⁺ → ferrioxamine

Ferrioxamine is considerably less biologically reactive than free iron and can subsequently be eliminated.

What Deferoxamine Does NOT Remove

Deferoxamine preferentially binds accessible toxic iron rather than stripping iron from essential physiologic proteins.

It does not substantially remove iron normally incorporated into:

• Hemoglobin
• Cytochromes
• Ferritin under usual acute treatment conditions
• Transferrin-bound iron under normal saturation conditions

This relative selectivity allows chelation of toxic iron while limiting disruption of essential iron-dependent functions.

Ferrioxamine Elimination

The iron–deferoxamine complex is eliminated substantially through the kidneys.

It can produce the classic:

Pink, reddish, or “vin rosé” urine

However:

Absence of pink or red urine does NOT mean deferoxamine is ineffective and does not exclude serious iron poisoning.

Urine color should never determine whether treatment is necessary.

Clinical Course of Acute Iron Poisoning

Acute iron poisoning classically progresses through several possible phases, although patients do not always follow a textbook sequence.

Early GI Phase

Possible findings include:

• Vomiting
• Abdominal pain
• Diarrhea
• Hematemesis
• Hematochezia
• Lethargy

Severe GI symptoms suggest significant corrosive and systemic toxicity.

Apparent Improvement

Symptoms may temporarily improve.

This latent period can be misleading because systemic toxicity may still evolve.

Systemic Toxicity

Severe poisoning may produce:

• Tachycardia
• Hypotension
• Shock
• High-anion-gap metabolic acidosis
• Altered mental status
• Seizures
• Coagulopathy
• Multiorgan dysfunction

Hepatic Injury

Delayed severe poisoning may produce:

• Markedly elevated aminotransferases
• Hypoglycemia
• Coagulopathy
• Acute liver failure

Late GI Scarring

Weeks later, severe corrosive GI injury can occasionally cause:

• Gastric outlet obstruction
• Other gastrointestinal strictures

When to Consider Deferoxamine

Chelation is primarily considered when there is evidence of significant systemic iron toxicity.

Important clinical findings include:

• Persistent severe vomiting or diarrhea
• GI bleeding
• Altered mental status
• Persistent tachycardia
• Hypotension or shock
• Significant metabolic acidosis
• Evidence of systemic deterioration

The overall clinical condition is more important than any isolated number.

Serum Iron Concentration

A serum iron concentration can help estimate severity when obtained at an appropriate time after an acute ingestion.

Important principles:

• Obtain the concentration during the expected absorption period.
• Interpret it together with symptoms and timing.
• A concentration obtained too early may underestimate the eventual peak.
• Delayed-release preparations can complicate interpretation.
• A single value should not override severe clinical toxicity.

Historically, concentrations around or above 500 µg/dL have been associated with substantial toxicity, but modern treatment decisions should not depend on a rigid threshold alone.

Do Not Delay Treatment in Severe Poisoning

A critically ill patient with a convincing iron exposure and manifestations such as:

• Shock
• Severe acidosis
• Significant CNS toxicity

may require chelation before a definitive serum iron result becomes available.

Clinical deterioration takes priority over waiting for laboratory confirmation.

Serum Iron After Deferoxamine

Once deferoxamine has been administered, interpretation of some serum iron measurements becomes problematic because laboratory methods may measure iron differently in the presence of chelator or ferrioxamine.

Therefore:

Pre-chelation iron concentrations are generally more useful for initial assessment.

Subsequent treatment should emphasize the overall clinical course rather than repeatedly chasing potentially misleading iron values.

TIBC Is Not a Reliable Severity Test

Historically, clinicians sometimes compared serum iron with total iron-binding capacity (TIBC).

This is unreliable in acute poisoning.

TIBC should not be used to determine:

• Whether serious toxicity exists
• Whether chelation is required
• When deferoxamine should be stopped

Route of Administration

For significant acute systemic iron poisoning:

Continuous IV deferoxamine is preferred.

Intramuscular administration is generally unsuitable for seriously poisoned patients because:

• Absorption may be unreliable
• Shock reduces muscle perfusion
• IV access is already necessary for resuscitation
• IM administration can cause local pain and complications

Oral deferoxamine is not appropriate for systemic chelation.

Duration of Therapy

Deferoxamine should be individualized according to:

• Hemodynamic improvement
• Resolution of metabolic acidosis
• Improvement in mental status
• Reduction of GI/systemic toxicity
• Renal function
• Overall clinical course

Many acute cases do not require prolonged treatment.

Long treatment courses increase the risk of adverse effects.

Hypotension

One of the most important acute adverse effects of deferoxamine is hypotension, particularly when administered too rapidly.

This is especially problematic because severe iron poisoning itself can cause:

• Vasodilation
• Volume depletion
• Shock

If hypotension develops during therapy, consider both the poisoning and treatment as possible contributors.

Hypersensitivity Reactions

Deferoxamine can rarely cause:

• Flushing
• Urticaria
• Hypotension
• Anaphylactoid or hypersensitivity reactions

Rapid administration can increase the risk of hemodynamic adverse effects.

Pulmonary Toxicity

Prolonged high-intensity deferoxamine treatment in acute poisoning has been associated with:

• Acute lung injury
• Pulmonary edema
• ARDS-like respiratory failure

This is one reason unnecessary prolonged treatment should be avoided.

Yersinia Infection

A distinctive complication of deferoxamine therapy is increased susceptibility to certain infections, particularly:

Yersinia enterocolitica

Deferoxamine can function as a siderophore-like iron source for Yersinia, allowing the organism to access iron more effectively.

This concern is particularly relevant during prolonged therapy or chronic iron overload.

Mucormycosis

Deferoxamine has also been associated with invasive fungal infection caused by Mucorales, particularly in susceptible patients such as those with:

• Renal failure
• Chronic iron or aluminum overload
• Prolonged deferoxamine exposure

This is far less relevant to a brief uncomplicated emergency course but remains an important pharmacologic association.

Ocular Toxicity

Long-term or excessive deferoxamine exposure can cause:

• Reduced visual acuity
• Abnormal color vision
• Visual-field abnormalities
• Night-vision impairment
• Retinal or optic-nerve toxicity

These effects are mainly associated with chronic therapy rather than brief acute chelation.

Auditory Toxicity

Chronic deferoxamine treatment can also produce:

• Tinnitus
• Sensorineural hearing loss

Long-term patients may therefore require periodic auditory assessment.

Renal Function

Renal impairment complicates deferoxamine therapy because ferrioxamine is substantially renally eliminated.

Monitor:

• Creatinine
• Urine output
• Fluid status
• Electrolytes

Renal injury can arise from the original iron poisoning, shock, or treatment-related factors.

Deferoxamine and Dialysis

A key distinction:

Free iron itself is not effectively removed by conventional hemodialysis because of its distribution and protein binding.

However, extracorporeal therapy may have a role in selected patients with:

• Severe renal failure
• Accumulation of ferrioxamine or related complexes
• Severe metabolic or renal complications requiring dialysis independently

This should be managed with toxicology and nephrology input rather than assuming dialysis is routinely indicated for iron poisoning.

Activated Charcoal

Activated charcoal does not effectively adsorb iron.

Therefore:

Iron poisoning → activated charcoal is not useful for the iron itself.

If a mixed ingestion occurred, charcoal might still have a role for an appropriate coingestant, provided the airway and gastrointestinal situation are suitable.

Whole-Bowel Irrigation

Because iron is not effectively bound by charcoal, whole-bowel irrigation (WBI) may be considered in selected substantial ingestions when tablets remain within the gastrointestinal tract.

This is particularly relevant when:

• A large tablet burden is visible on imaging
• The patient has a substantial ingestion
• Gastrointestinal function is adequate

WBI is not appropriate with obstruction, ileus, perforation, severe instability, or an inadequately protected airway.

Abdominal Imaging

Iron tablets are often radiopaque.

Abdominal radiography may therefore demonstrate:

• Tablets
• Pill concretions
• Large retained gastrointestinal burdens

However:

A negative radiograph does not completely exclude iron ingestion.

Imaging is an adjunct to the clinical and laboratory assessment.

Ascorbic Acid

Vitamin C can alter iron mobilization and iron-chelator dynamics.

It is not routinely added to the acute treatment of iron overdose.

Its use in chronic iron-overload therapy is a different situation and requires careful specialist supervision.

Chronic Iron Overload

Repeated blood transfusions can cause progressive iron accumulation because the body has no efficient physiologic mechanism for eliminating large excesses of iron.

Chronic iron overload can damage:

• Liver
• Heart
• Endocrine organs
• Other tissues

Deferoxamine has historically been an important treatment, often through prolonged subcutaneous administration.

Other modern iron chelators, including oral agents, may also be used depending on the underlying condition.

Aluminum Overload

Deferoxamine can also chelate aluminum.

It has historically been used for significant aluminum accumulation, particularly in patients receiving long-term dialysis.

This is now a specialized indication and should be managed with nephrology/toxicology expertise.

Pregnancy

The historical FDA Category C designation is obsolete.

Severe maternal iron poisoning is potentially fatal and itself threatens the fetus.

Therefore:

Pregnancy should not prevent necessary deferoxamine treatment for serious maternal iron poisoning.

Maternal stabilization takes priority.

Monitoring During Acute Iron Poisoning

Important monitoring includes:

• Airway and breathing
• Continuous cardiovascular monitoring in severe cases
• Blood pressure and perfusion
• Mental status
• Blood glucose
• Electrolytes
• Bicarbonate and anion gap
• Blood gas and lactate when severely ill
• Renal function
• Urine output
• Liver enzymes
• Coagulation studies in significant poisoning
• Appropriately timed serum iron concentration

Serial reassessment is essential because toxicity can evolve after an apparent period of improvement.

Important Modernization of the Older Source

Several points require clarification:

• Deferoxamine remains an important antidote for severe systemic iron poisoning.
• Treatment should be based on the overall clinical syndrome, timing, serum iron concentration, metabolic abnormalities, and hemodynamic status—not a rigid serum iron cutoff alone.
• Do not delay deferoxamine in a severely symptomatic patient while awaiting an iron concentration.
• IV infusion is preferred for significant acute poisoning; IM therapy has little role in critically ill patients.
• The classic vin rosé urine finding is neither required nor sufficiently reliable to guide treatment.
• TIBC is not useful for determining the severity of acute iron poisoning.
• Serum iron measurements can become difficult to interpret after chelation begins.
• Activated charcoal does not meaningfully bind iron.
• WBI may be useful for selected large tablet burdens.
• Prolonged deferoxamine treatment increases the risk of pulmonary toxicity and other complications.
• Deferoxamine is associated with Yersinia and, particularly in susceptible chronic-treatment patients, Mucorales infection.
• Hemodialysis does not simply remove the original iron burden; its role is mainly selected renal/metabolic situations and potentially removal of circulating chelated complexes.
• Historical FDA pregnancy categories are obsolete; severe maternal poisoning warrants treatment.

Key Points

• Deferoxamine is a major antidote for severe acute iron poisoning.
• It chelates ferric iron (Fe³⁺) to form ferrioxamine.
• Ferrioxamine is substantially renally eliminated.
• Severe iron toxicity can cause corrosive GI injury, shock, high-anion-gap metabolic acidosis, CNS toxicity, hepatic failure, and multiorgan dysfunction.
• An apparent symptom-free period does not guarantee recovery.
• Severe symptomatic poisoning can justify chelation before the iron concentration returns.
• Serum iron values must be interpreted according to timing and clinical findings.
• TIBC is not a reliable guide to acute iron toxicity.
• IV deferoxamine is preferred for serious systemic poisoning.
• Rapid administration can cause significant hypotension.
• Prolonged treatment can contribute to pulmonary toxicity.
• Chronic therapy can produce ocular and auditory toxicity.
• Deferoxamine is associated with increased susceptibility to Yersinia and certain invasive fungal infections.
• Activated charcoal does not adsorb iron effectively.
• Selected large tablet ingestions may be candidates for whole-bowel irrigation.
• Pink or “vin rosé” urine may occur during chelation, but its absence does not exclude toxicity or treatment effect.
• Pregnancy is not a reason to withhold necessary chelation in life-threatening maternal iron poisoning.